## Abraham Weizman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2152323/publications.pdf

Version: 2024-02-01

709 papers

24,283 citations

69 h-index 23533 111 g-index

720 all docs 720 docs citations

times ranked

720

21616 citing authors

#	Article	IF	CITATIONS
1	The Association between ADHD and the Severity of COVID-19 Infection. Journal of Attention Disorders, 2022, 26, 491-501.	2.6	27
2	COVID-19 pandemic: Impacts on mothers' and infants' mental health during pregnancy and shortly thereafter. Clinical Child Psychology and Psychiatry, 2022, 27, 82-88.	1.6	11
3	Phenotypic Characterization of Youth Admitted To Acute Psychiatric Inpatient Unit Following Self-Harm Behavior. Archives of Suicide Research, 2022, 26, 1186-1197.	2.3	1
4	Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome. World Journal of Biological Psychiatry, 2022, 23, 475-482.	2.6	2
5	Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review. International Journal of Environmental Research and Public Health, 2022, 19, 523.	2.6	4
6	Complex Effects of Sertraline and Citalopram on In Vitro Murine Breast Cancer Proliferation and on In Vivo Progression and Anxiety Level. International Journal of Molecular Sciences, 2022, 23, 2711.	4.1	1
7	Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antidepressant Treatment. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 153-161.	1.3	1
8	The Effect of Natural-Based Formulation (NBF) on the Response of RAW264.7 Macrophages to LPS as an In Vitro Model of Inflammation. Journal of Fungi (Basel, Switzerland), 2022, 8, 321.	3.5	5
9	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
10	Neutrophil to-lymphocyte and platelet-to-lymphocyte ratios as biomarkers for suicidal behavior in children and adolescents with depression or anxiety treated with selective serotonin reuptake inhibitors. Brain, Behavior, and Immunity, 2022, 104, 31-38.	4.1	12
11	Clinical and Socio-Demographic Variables Associated with the Diagnosis of Long COVID Syndrome in Youth: A Population-Based Study. International Journal of Environmental Research and Public Health, 2022, 19, 5993.	2.6	24
12	Callous-Unemotional Traits and Face-Emotion Recognition as Mediators in Conduct Problems of Children With ADHD. Clinical Child Psychology and Psychiatry, 2022, 27, 978-990.	1.6	1
13	Clozapine blood level assessment using a point-of-care device: feasibility and reliability. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532210944.	2.7	1
14	ADHD as a Risk Factor for Infection With Covid-19. Journal of Attention Disorders, 2021, 25, 1783-1790.	2.6	65
15	Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease. Molecular Psychiatry, 2021, 26, 2626-2632.	7.9	36
16	Differential methylation of imprinting genes and MHC locus in 22q11.2 deletion syndrome-related schizophrenia spectrum disorders. World Journal of Biological Psychiatry, 2021, 22, 46-57.	2.6	10
17	Possible Age-Related Progression of Attentional Impairment in ADHD and Its Attenuation by Past Diagnosis and Treatment. Journal of Attention Disorders, 2021, 25, 14-21.	2.6	6
18	Regulatory effect of lithium on hippocampal bloodâ€brain barrier integrity in a rat model of depressiveâ€like behavior. Bipolar Disorders, 2021, 23, 55-65.	1.9	32

#	Article	IF	CITATIONS
19	The Placebo Response in Adult ADHD as Objectively Assessed by the TOVA Continuous Performance Test. Journal of Attention Disorders, 2021, 25, 1311-1320.	2.6	2
20	Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment. Cellular and Molecular Neurobiology, 2021, 41, 1019-1029.	3.3	21
21	Development and validation of a machine learningâ€based postpartum depression prediction model: A nationwide cohort study. Depression and Anxiety, 2021, 38, 400-411.	4.1	39
22	Chronic opipramol treatment extinguishes cocaine craving through Rac1 in responders: A rat model study. Addiction Biology, 2021, 26, e13014.	2.6	4
23	Association between Adherence to SSRI Treatment and Mortality among Individuals with Metabolic Syndrome Components. Pharmacopsychiatry, 2021, 54, 232-239.	3.3	5
24	Elevated rate of OCD-spectrum and tic disorders in patients with bipolar depression and comorbid OCD. Journal of Obsessive-Compulsive and Related Disorders, 2021, 29, 100643.	1.5	2
25	Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone. Journal of Psychopharmacology, 2021, 35, 1134-1140.	4.0	2
26	The TSPO Ligands MGV-1 and 2-Cl-MGV-1 Differentially Inhibit the Cigarette Smoke-Induced Cytotoxicity to H1299 Lung Cancer Cells. Biology, 2021, 10, 395.	2.8	0
27	Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome – Clinical and scientific implications. Schizophrenia Research, 2021, 231, 164-169.	2.0	3
28	Mood and Proneness to Boredom Are Associated with Poorer Continuous Performance Test Results, Which May Improve with Methylphenidate Treatment, in Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 310-314.	1.3	2
29	The relationship between the plasma proinflammatory cytokine levels of depressed/anxious children and their parents. Scientific Reports, 2021, 11, 11798.	3.3	2
30	Genome wide analysis implicates upregulation of proteasome pathway in major depressive disorder. Translational Psychiatry, 2021, 11, 409.	4.8	2
31	Stimulant Treatment Effect on Anxiety Domains in Children with Attention-Deficit/Hyperactivity Disorder With and Without Anxiety Disorders: A 12-Week Open-Label Prospective Study. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 639-644.	1.3	1
32	Rate of OCD and sub-threshold OCD in bipolar disorder patients with first depressive episode. Psychiatry Research, 2021, 302, 114010.	3.3	2
33	Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy. Journal of Psychiatric Research, 2021, 141, 92-103.	3.1	5
34	Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression. Brain, Behavior, & Immunity - Health, 2021, 16, 100313.	2.5	9
35	The association of medical resource utilization with physical morbidity and premature mortality among patients with schizophrenia: An historical prospective population cohort study. Schizophrenia Research, 2021, 237, 62-68.	2.0	7
36	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, 2021, 26, 4496-4510.	7.9	87

#	Article	IF	CITATIONS
37	Beneficial effect of quetiapine monotherapy in patients with bipolar depression and comorbid obsessive-compulsive disorder. International Clinical Psychopharmacology, 2021, 36, 50-53.	1.7	9
38	Management of anxiety disorders in children with attention-deficit hyperactivity disorder: a narrative review. International Clinical Psychopharmacology, 2021, 36, 1-11.	1.7	1
39	The Neuro-Protective Effects of the TSPO Ligands CB86 and CB204 on 6-OHDA-Induced PC12 Cell Death as an In Vitro Model for Parkinson's Disease. Biology, 2021, 10, 1183.	2.8	O
40	The Effect of Dehydroepiandrosterone Treatment on Neurogenesis, Astrogliosis and Long-Term Cocaine-Seeking Behavior in a Cocaine Self-Administration Model in Rats. Frontiers in Neuroscience, 2021, 15, 773197.	2.8	3
41	Continuous Performance Test Is Sensitive to a Single Methylphenidate Challenge in Preschool Children With ADHD. Journal of Attention Disorders, 2020, 24, 226-234.	2.6	3
42	Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review. European Child and Adolescent Psychiatry, 2020, 29, 1035-1048.	4.7	18
43	Predictors of Suicidal Behaviors during Hospitalization among Adolescents Admitted Due to Suicidal Behaviors: A 10-Year Retrospective Naturalistic Study. Archives of Suicide Research, 2020, 24, S202-S216.	2.3	1
44	Characterizing the Placebo Response in Adults With ADHD. Journal of Attention Disorders, 2020, 24, 425-433.	2.6	7
45	A retrospective case series of electroconvulsive therapy in the management of comorbid depression and anorexia nervosa. International Journal of Eating Disorders, 2020, 53, 210-218.	4.0	14
46	Association between prenatal exposure to a 1-month period of repeated rocket attacks and neuropsychiatric outcomes up through age 9: a retrospective cohort study. European Child and Adolescent Psychiatry, 2020, 29, 1135-1142.	4.7	3
47	Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects. American Journal of Human Genetics, 2020, 106, 26-40.	6.2	42
48	Increased circulatory IL-6 during 8-week fluoxetine treatment is a risk factor for suicidal behaviors in youth. Brain, Behavior, and Immunity, 2020, 87, 301-308.	4.1	22
49	Poor performance of the â€~child Reading the Mind in the Eyes Test' correlates with poorer social-emotional functioning in children with attention-deficit/hyperactivity disorder. International Clinical Psychopharmacology, 2020, 35, 105-108.	1.7	6
50	Beneficial Effect of a Relatively Low Dose of Clozapine in a Bipolar Depression Patient With Comorbid Obsessive-Compulsive Disorder and Severe Suicidality. Clinical Neuropharmacology, 2020, 43, 169-170.	0.7	4
51	Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges. International Clinical Psychopharmacology, 2020, 35, 300-304.	1.7	1
52	Thyroid function assessment before and after diagnosis of schizophrenia: A community-based study. Psychiatry Research, 2020, 293, 113356.	3.3	13
53	Association of Risperidone Treatment and Change in BMI in Children Under 5 Years Old: A Retrospective Cohort Study. Biological Psychiatry, 2020, 87, S254-S255.	1.3	0
54	The Effect of Clozapine and Another Antipsychotic Combination Treatment on the Clinical Outcomes of Treatment Resistant Schizophrenia Inpatients. Biological Psychiatry, 2020, 87, S344.	1.3	0

#	Article	IF	CITATIONS
55	An increase in IL-6 levels at 6-month follow-up visit is associated with SSRI-emergent suicidality in high-risk children and adolescents treated with fluoxetine. European Neuropsychopharmacology, 2020, 40, 61-69.	0.7	13
56	Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 486-494.	1.3	5
57	The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells. Biology, 2020, 9, 291.	2.8	4
58	Metabolic predictors for mortality among patients treated with long-term clozapine – A longitudinal study. European Neuropsychopharmacology, 2020, 41, 63-69.	0.7	10
59	The association of non-suicidal self-injurious and suicidal behaviors with religiosity in hospitalized Jewish adolescents. Clinical Child Psychology and Psychiatry, 2020, 25, 801-815.	1.6	3
60	Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists. Drugs, 2020, 80, 871-882.	10.9	20
61	Efficaciousness of Low Affinity Compared to High Affinity TSPO Ligands in the Inhibition of Hypoxic Mitochondrial Cellular Damage Induced by Cobalt Chloride in Human Lung H1299 Cells. Biomedicines, 2020, 8, 106.	3.2	6
62	Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users. Frontiers in Psychiatry, 2020, 11, 355.	2.6	7
63	18-kDa Translocator Protein Ligands Protect H9C2 Cardiomyocytes from Cigarette Smoke-induced Cell Death: <i>In Vitro</i> Study. In Vivo, 2020, 34, 549-556.	1.3	2
64	Low levels of serum vitamin D in clozapine-treated schizophrenia patients are associated with high levels of the proinflammatory cytokine IL-6. International Clinical Psychopharmacology, 2020, 35, 208-213.	1.7	7
65	Levels of Proneness to Boredom in Children with Attention-Deficit/Hyperactivity Disorder On and Off Methylphenidate Treatment. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 173-176.	1.3	13
66	Long-term effects of intracranial islet grafting on cognitive functioning in a rat metabolic model of sporadic Alzheimer's disease-like dementia. PLoS ONE, 2020, 15, e0227879.	2.5	3
67	Comorbid personality disorders in manic bipolar I disorder patients is associated with increased use of long-acting injectable antipsychotic treatment and higher rates of rehospitalization. International Clinical Psychopharmacology, 2020, 35, 74-80.	1.7	1
68	Lack of association between unipolar or bipolar depression and serum aquaporin-4 autoantibodies. Brain, Behavior, and Immunity, 2020, 88, 930-934.	4.1	6
69	The protective effect of the TSPO ligands 2,4-Di-Cl-MGV-1, CB86, and CB204 against LPS-induced M1 pro-inflammatory activation of microglia. Brain, Behavior, & Immunity - Health, 2020, 5, 100083.	2.5	11
70	Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome. European Child and Adolescent Psychiatry, 2019, 28, 31-42.	4.7	21
71	Demographic and Clinical Predictors of Hospitalization in Preschoolers With ADHD. Journal of Attention Disorders, 2019, 23, 1284-1290.	2.6	0
72	Effects of Cigarette Smoke on TSPO-related Mitochondrial Processes. Cells, 2019, 8, 694.	4.1	15

#	Article	IF	CITATIONS
73	Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: A nationwide cohort study. Depression and Anxiety, 2019, 36, 921-929.	4.1	25
74	The contribution of ADHD and attachment difficulties to online pornography use among students. Comprehensive Psychiatry, 2019, 93, 56-60.	3.1	16
75	A history of prolonged childhood sexual abuse is associated with more severe clinical presentation of borderline personality disorder in adolescent female inpatients – A naturalistic study. Child Abuse and Neglect, 2019, 98, 104222.	2.6	15
76	Cigarette smoke, saliva, the translocator protein 18ÂkDa (TSPO), and oral cancer. Oral Diseases, 2019, 25, 1843-1849.	3.0	3
77	Do young women with tattoos have lower self-esteem and body image than their peers without tattoos? A non-verbal repertory grid technique approach. PLoS ONE, 2019, 14, e0206411.	2.5	13
78	Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clinical Pharmacology and Therapeutics, 2019, 105, 1139-1147.	4.7	152
79	Inhibitory Effects of the Two Novel TSPO Ligands 2-Cl-MGV-1 and MGV-1 on LPS-induced Microglial Activation. Cells, 2019, 8, 486.	4.1	27
80	Comparing executive functioning and clinical and sociodemographic characteristics of people with schizophrenia who hold a driver's license to those who do not. Canadian Journal of Occupational Therapy, 2019, 86, 70-80.	1.3	2
81	The complexity of the interaction between binge-eating and attention. PLoS ONE, 2019, 14, e0215506.	2.5	2
82	Modulatory effects of cannabinoids on brain neurotransmission. European Journal of Neuroscience, 2019, 50, 2322-2345.	2.6	64
83	Equine Assisted Therapy for Patients with Post Traumatic Stress Disorder: A Case Series Study. Military Medicine, 2019, 184, 394-399.	0.8	21
84	Psychiatrists' attitude towards the use of clozapine in the treatment of refractory schizophrenia: A nationwide survey. Psychiatry Research, 2019, 275, 155-161.	3.3	24
85	Risk gene-set and pathways in 22q11.2 deletion-related schizophrenia: a genealogical molecular approach. Translational Psychiatry, 2019, 9, 15.	4.8	13
86	Apparent lack of practice effects in the Test of Variables of Attention (TOVA) in adult ADHD. ADHD Attention Deficit and Hyperactivity Disorders, 2019, 11, 73-81.	1.7	8
87	The TSPO Ligands 2-Cl-MGV-1, MGV-1, and PK11195 Differentially Suppress the Inflammatory Response of BV-2 Microglial Cell to LPS. International Journal of Molecular Sciences, 2019, 20, 594.	4.1	33
88	The role of inhibition capacities in the lowa gambling test performance in young tattooed women. BMC Psychology, 2019, 7, 87.	2.1	1
89	The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder. International Clinical Psychopharmacology, 2019, 34, 179-183.	1.7	5
90	Trafficking of Grafted Pancreatic Islets Into the Brain Lateral Ventricles: Implications for Cognition. Transplantation, 2019, 103, e137-e138.	1.0	1

#	Article	IF	Citations
91	High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder. International Clinical Psychopharmacology, 2019, 34, 138-142.	1.7	5
92	Beneficial Effect of Betahistine, a Structural Analog of Histamine, in Clozapine-Related Sedation. Clinical Neuropharmacology, 2019, 42, 145-145.	0.7	5
93	Add-on benzodiazepines for psychosis-induced aggression. International Clinical Psychopharmacology, 2019, 34, 119-123.	1.7	4
94	Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 90-96.	4.8	70
95	Obsessive–compulsive symptomatology in female adolescent inpatients with restrictive compared with binge–purge eating disorders. European Eating Disorders Review, 2019, 27, 224-235.	4.1	6
96	Symptoms Versus Impairment in Adults With ADHD: Intercorrelations of the BRIEF-A, CAARS, and TOVA. Journal of Attention Disorders, 2019, 23, 1557-1566.	2.6	5
97	High Familial Correlation in Methylphenidate Response and Side Effect Profile. Journal of Attention Disorders, 2019, 23, 135-139.	2.6	5
98	Changes in consumption of opioid analgesics in Israel 2009 to 2016: An update focusing on oxycodone and fentanyl formulations. Pharmacoepidemiology and Drug Safety, 2018, 27, 535-540.	1.9	14
99	Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder. International Clinical Psychopharmacology, 2018, 33, 229-232.	1.7	6
100	Elevated neutrophil to lymphocyte ratio in non-affective psychotic adolescent inpatients: Evidence for early association between inflammation and psychosis. Psychiatry Research, 2018, 262, 149-153.	3.3	33
101	Adjunctive antidepressants in bipolar depression: A cohort study of six- and twelve-months rehospitalization rates. European Neuropsychopharmacology, 2018, 28, 353-360.	0.7	3
102	Predictors of developing mathematics anxiety among middleâ€school students: A 2â€year prospective study. International Journal of Psychology, 2018, 53, 426-432.	2.8	18
103	Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment. Schizophrenia Research, 2018, 192, 226-231.	2.0	23
104	The effect of methylphenidate treatment on suspiciousness in children with ADHD alone or comorbid with ODD. International Journal of Psychiatry in Clinical Practice, 2018, 22, 109-114.	2.4	3
105	In vitro Effects of the Specific Mitochondrial TSPO Ligand Ro5 4864 in Cultured Human Osteoblasts. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 77-84.	1.2	5
106	No apparent association between bipolar disorder and cancer in a large epidemiological study of outpatients in a managed care population. International Clinical Psychopharmacology, 2018, 33, 73-78.	1.7	9
107	Higher adaptive functioning and lower rate of psychotic comorbidity in married versus unmarried individuals with 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 2365-2374.	1.2	3
108	The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder. International Clinical Psychopharmacology, 2018, 33, 330-333.	1.7	3

#	Article	IF	CITATIONS
109	The role of gender in association between inhibition capacities and risky decision making. Psychology Research and Behavior Management, 2018, Volume 11, 503-510.	2.8	11
110	Distinct Response Inhibition Patterns in Obsessive Compulsive Disorder Patients and Pathological Gamblers. Frontiers in Psychiatry, 2018, 9, 652.	2.6	8
111	A DNA Methylation Signature of Addiction in T Cells and Its Reversal With DHEA Intervention. Frontiers in Molecular Neuroscience, 2018, 11, 322.	2.9	14
112	Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia. Journal of Clinical Psychopharmacology, 2018, 38, 609-611.	1.4	9
113	Intracranial Transplantation of Pancreatic Islets Attenuates Cognitive and Peripheral Metabolic Dysfunctions in a Rat Model of Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 1445-1458.	2.6	6
114	Dehydroepiandrosterone and Addiction. Vitamins and Hormones, 2018, 108, 385-412.	1.7	1
115	Differences in demographic and clinical characteristics between cannabis users and non-drug users: A retrospective study of patients at first hospitalization due to psychotic symptoms. Psychiatry Research, 2018, 268, 454-459.	3.3	3
116	The Impact of Prolonged, Selective, Serotonin Reuptake Inhibitor Treatment on Serum Lipid and Glucose Levels in Children and Adolescents: A Preliminary Prospective Study. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 485-487.	1.3	1
117	The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 83-90.	1.3	30
118	Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study. Schizophrenia Research, 2017, 188, 42-49.	2.0	16
119	Insulin delivery to the brain using intracranial implantation of alginate-encapsulated pancreatic islets. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 3263-3272.	2.7	12
120	Trans-generation enrichment of clozapine-responsiveness trait in mice using a subchronic hypo-glutamatergic model of schizophrenia: A preliminary study. Behavioural Brain Research, 2017, 323, 141-145.	2.2	2
121	New developments in brain research of internet and gaming disorder. Neuroscience and Biobehavioral Reviews, 2017, 75, 314-330.	6.1	171
122	Ketamine upregulates eNOS expression in human astroglial A172 cells: Possible role in its antidepressive properties. Journal of Neuroimmunology, 2017, 305, 75-81.	2.3	2
123	BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction. Human Molecular Genetics, 2017, 26, 2462-2471.	2.9	41
124	The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 429-432.	1.3	10
125	Runs of homozygosity, copy number variation, and risk for depression and suicidal behavior in an Arab Bedouin kindred. Psychiatric Genetics, 2017, 27, 169-177.	1.1	5
126	The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. International Clinical Psychopharmacology, 2017, 32, 289-293.	1.7	20

#	Article	IF	Citations
127	Intracerebroventricular Streptozotocin Induces Obesity and Dementia in Lewis Rats. Journal of Alzheimer's Disease, 2017, 60, 121-136.	2.6	14
128	Low adherence to antidepressants is associated with increased mortality in Parkinson disease patients. Parkinsonism and Related Disorders, 2017, 43, 92-96.	2.2	15
129	Serum Ferritin Levels Are Lower in Children With Tic Disorders Compared with Children Without Tics: A Cross-Sectional Study. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 192-195.	1.3	7
130	Fibre tract analysis using diffusion tensor imaging reveals aberrant connectivity in a rat model of depression. World Journal of Biological Psychiatry, 2017, 18, 615-623.	2.6	13
131	Predictors of short-term outcome variables in hospitalised female adolescents with eating disorders. International Journal of Psychiatry in Clinical Practice, 2017, 21, 41-49.	2.4	19
132	4.45 Clinical Manifestations of 22q11.2 Deletion Syndrome and the Role of Prematurity in the Emergence of Psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, S244.	0.5	0
133	Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. EBioMedicine, 2017, 26, 138-145.	6.1	58
134	Nonfunctional Redundant Acts Characterize OCD, Even in OCD-Unrelated Tasks: A Demonstration in Questionnaire Completion. Psychopathology, 2017, 50, 389-400.	1.5	3
135	Association between Elevated C-Reactive Protein and Manic Polarity in Acute Psychiatric Inpatients with Affective Symptomatology. Neuropsychobiology, 2017, 76, 166-170.	1.9	1
136	No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System–Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder. Clinical Neuropharmacology, 2017, 40, 11-15.	0.7	2
137	Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users. Current Pharmaceutical Design, 2017, 22, 6366-6379.	1.9	58
138	Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits. Journal of Clinical Psychiatry, 2017, 78, e1219-e1225.	2.2	17
139	Gene polymorphisms potentially related to the pharmacokinetics of clozapine. International Clinical Psychopharmacology, 2016, 31, 179-184.	1.7	20
140	The clock-drawing test as a possible indicator of acute psychosis. International Clinical Psychopharmacology, 2016, 31, 155-158.	1.7	0
141	Effect of dehydroepiandrosterone add-on therapy on mood, decision making and subsequent relapse of polydrug users. Addiction Biology, 2016, 21, 885-894.	2.6	20
142	Psychiatric side effects of acute high-dose corticosteroid therapy in neurological conditions. International Clinical Psychopharmacology, 2016, 31, 224-231.	1.7	9
143	Antipsychotic adjunctive therapy to mood stabilizers and 1â€year rehospitalization rates in bipolar disorder: A cohort study. Bipolar Disorders, 2016, 18, 684-691.	1.9	9
144	Periodic patterning of the Drosophila eye is stabilized by the diffusible activator Scabrous. Nature Communications, 2016, 7, 10461.	12.8	28

#	Article	IF	Citations
145	Group cognitive behavioral treatment in female soldiers diagnosed with binge/purge eating disorders. Eating Disorders, 2016, 24, 338-353.	3.0	3
146	Do Antidepressants Induce Psychosis in Children and Adolescents? A Naturalistic Study in Ambulatory Pediatric Population. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 478-484.	1.3	5
147	Levels of depression and satisfaction with life as indicators of health services consumption. International Journal of Psychiatry in Clinical Practice, 2016, 20, 245-248.	2.4	3
148	Neurocognitive profile in psychotic versus nonpsychotic individuals with 22q11.2 deletion syndrome. European Neuropsychopharmacology, 2016, 26, 1610-1618.	0.7	45
149	Association between prematurity and the evolution of psychotic disorders in 22q11.2 deletion syndrome. Journal of Neural Transmission, 2016, 123, 1491-1497.	2.8	8
150	<i>CHRNA5/A3/B4</i> Variant rs3743078 and Nicotine-Related Phenotypes: Indirect Effects Through Nicotine Craving. Journal of Studies on Alcohol and Drugs, 2016, 77, 227-237.	1.0	4
151	Cigarette Smoking, Alcohol and Cannabis Use in Patients With Pervasive Developmental Disorders. Substance Use and Misuse, 2016, 51, 1415-1420.	1.4	4
152	Trends in the use of antipsychotics in the Israeli inpatient population, 2004–2013. Israel Journal of Health Policy Research, 2016, 5, 16.	2.6	1
153	Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. Journal of Neural Transmission, 2016, 123, 1347-1354.	2.8	20
154	Methadone treatment, bruxism, and temporomandibular disorders among male prisoners. European Journal of Oral Sciences, 2016, 124, 266-271.	1.5	6
155	The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 727-732.	1.3	57
156	Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine. Journal of Molecular Neuroscience, 2016, 58, 66-73.	2.3	1
157	The association between serum creatine kinase, mood and psychosis in inpatients with schizophrenia, bipolar and schizoaffective disorders. Psychiatry Research, 2016, 238, 333-337.	3.3	8
158	Seasonal pattern of manic episode admissions among bipolar I disorder patients is associated with male gender and presence of psychotic features. Journal of Affective Disorders, 2016, 190, 123-127.	4.1	20
159	Suicide, Satisfaction With Life, and Insight Capacity Among Adolescents With Mental Disorders. Crisis, 2016, 37, 347-352.	1.2	8
160	Adherence to Antidepressants Is Associated With Lower Mortality. Journal of Clinical Psychiatry, 2016, 77, e566-e572.	2.2	32
161	Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital. Journal of Clinical Psychiatry, 2016, 77, e989-e995.	2.2	25
162	Treatment of Antipsychotic-Related Akathisia Revisited. Journal of Clinical Psychopharmacology, 2015, 35, 711-714.	1.4	7

#	Article	IF	Citations
163	Impact of epilepsy and antiepileptic medications on the metabolic profile in adults with autism spectrum disorder and intellectual disabilities. International Clinical Psychopharmacology, 2015, 30, 351-355.	1.7	1
164	Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients. International Clinical Psychopharmacology, 2015, 30, 241-248.	1.7	10
165	Intracranial pancreatic islet transplantation increases islet hormone expression in the rat brain and attenuates behavioral dysfunctions induced by MK-801 (dizocilpine). Hormones and Behavior, 2015, 72, 1-11.	2.1	10
166	The Association in Elderly Hospitalized Patients, Between Psychotropic Drugs and Hip Fractures Resulting from Falls. Experimental Aging Research, 2015, 41, 546-555.	1.2	10
167	Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration. Behavioural Brain Research, 2015, 282, 125-132.	2.2	26
168	Adherence to antidepressant therapy and mortality rates in ischaemic heart disease: cohort study. British Journal of Psychiatry, 2015, 206, 297-301.	2.8	21
169	Thymic and bone marrow output in individuals with 22q11.2 deletion syndrome. Pediatric Research, 2015, 77, 579-585.	2.3	18
170	Effects of the Anti-Multiple Sclerosis Immunomodulator Laquinimod on Anxiety and Depression in Rodent Behavioral Models. Journal of Molecular Neuroscience, 2015, 55, 552-560.	2.3	3
171	Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome. JAMA Psychiatry, 2015, 72, 377.	11.0	196
172	SSRI-Induced Activation Syndrome in Children and Adolescentsâ€"What Is Next?. Current Treatment Options in Psychiatry, 2015, 2, 28-37.	1.9	24
173	The impact of age and gender on adherence to antidepressants: a 4-year population-based cohort study. Psychopharmacology, 2015, 232, 3385-3390.	3.1	32
174	A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1006-1020.	2.3	87
175	Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 785-802.	2.3	122
176	Immunomodulatory activity of ketamine in human astroglial A172 cells: Possible relevance to its rapid antidepressant activity. Journal of Neuroimmunology, 2015, 282, 33-38.	2.3	18
177	Opposing Effects of Oxytocin on Overt Compliance and Lasting Changes to Memory. Neuropsychopharmacology, 2015, 40, 966-973.	5.4	23
178	Effect of Clozapine and Other Antipsychotics on the Level of Platelet-Associated Autoantibodies in Children with Schizophrenia: A Longitudinal Follow-Up Study. Neuropsychobiology, 2015, 71, 120-124.	1.9	2
179	Post-SSRI Sexual Dysfunction. Journal of Clinical Psychopharmacology, 2015, 35, 273-278.	1.4	40
180	Authors' reply. British Journal of Psychiatry, 2015, 207, 270-270.	2.8	0

#	Article	IF	CITATIONS
181	The Impact of Chronic Early Administration of Psychostimulants on Brain Expression of BDNF and Other Neuroplasticity-Relevant Proteins. Journal of Molecular Neuroscience, 2015, 57, 231-242.	2.3	20
182	Hyperactive auditory processing in Williams syndrome: Evidence from auditory evoked potentials. Psychophysiology, 2015, 52, 782-789.	2.4	36
183	Baclofen as Add-On to Standard Psychosocial Treatment for Alcohol Dependence: a Randomized, Double-Blind, Placebo-Controlled Trial With 1Year Follow-Up. Journal of Substance Abuse Treatment, 2015, 52, 24-30.	2.8	69
184	International Society for Bipolar Disorders Task Force on Suicide: metaâ€analyses and metaâ€regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disorders, 2015, 17, 1-16.	1.9	265
185	Childhood adversity moderates the effect of <i> ADH1B &lt; /i &gt; on risk for alcohol-related phenotypes in Jewish Israeli drinkers. Addiction Biology, 2015, 20, 205-214.</i>	2.6	28
186	Dental Health and the Type of Antipsychotic Treatment in Inpatients with Schizophrenia. Israel Journal of Psychiatry, 2015, 52, 114-8.	0.2	2
187	Alcohol Consumption Mediates the Relationship Between <i>ADH1B</i> and DSM-IV Alcohol Use Disorder and Criteria. Journal of Studies on Alcohol and Drugs, 2014, 75, 635-642.	1.0	9
188	Parental Alcohol History Differentially Predicts Offspring Disorders in Distinct Subgroups in Israel. Journal of Studies on Alcohol and Drugs, 2014, 75, 859-869.	1.0	7
189	Short-Term Effects of Lithium on White Blood Cell Counts and on Levels of Serum Thyroid-Stimulating Hormone and Creatinine in Adolescent Inpatients: A Retrospective Naturalistic Study. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 494-500.	1.3	18
190	The beneficial effect of escitalopram on obsessive–compulsive-related musical hallucinations in elderly patients with hearing impairment. International Clinical Psychopharmacology, 2014, 29, 263-265.	1.7	8
191	The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety. International Clinical Psychopharmacology, 2014, 29, 274-278.	1.7	14
192	Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression. World Journal of Biological Psychiatry, 2014, 15, 76-82.	2.6	22
193	Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. International Clinical Psychopharmacology, 2014, 29, 296-298.	1.7	15
194	Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia. International Clinical Psychopharmacology, 2014, 29, 212-215.	1.7	23
195	Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2014, 171, 627-639.	<b>7.</b> 2	645
196	Pharmacological and behavioral management of some often-overlooked clozapine-induced side effects. International Clinical Psychopharmacology, 2014, 29, 313-317.	1.7	19
197	Association between bipolar episodes and fluid and electrolyte homeostasis: a retrospective longitudinal study. Bipolar Disorders, 2014, 16, 781-789.	1.9	11
198	Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel. Comprehensive Psychiatry, 2014, 55, 621-630.	3.1	47

#	Article	IF	Citations
199	Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects. Journal of Psychiatric Research, 2014, 56, 28-35.	3.1	22
200	Shyness discriminates between children with 22q11.2 deletion syndrome and Williams syndrome and predicts emergence of psychosis in 22q11.2 deletion syndrome. Journal of Neurodevelopmental Disorders, 2014, 6, 3.	3.1	17
201	In vitro effect of FGIN-1-27, a ligand to 18ÂkDa mitochondrial translocator protein, in human osteoblast-like cells. Journal of Bioenergetics and Biomembranes, 2014, 46, 197-204.	2.3	12
202	Metabolic Effects of Antipsychotics in Prepubertal Children: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 218-222.	1.3	6
203	Exposure to the Lebanon War of 2006 and effects on alcohol use disorders: The moderating role of childhood maltreatment. Drug and Alcohol Dependence, 2014, 134, 296-303.	3.2	16
204	Cognitive traits in inpatient adolescents with and without prior suicide attempts and non-suicidal self-injury. Comprehensive Psychiatry, 2014, 55, 370-373.	3.1	19
205	A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. European Neuropsychopharmacology, 2014, 24, 425-436.	0.7	8
206	Intrusive trauma recollections is associated with impairment of interference inhibition and psychomotor speed in PTSD. Comprehensive Psychiatry, 2014, 55, 1587-1594.	3.1	15
207	Parental psychopathology moderates the influence of parental divorce on lifetime alcohol use disorders among Israeli adults. Drug and Alcohol Dependence, 2014, 141, 85-91.	3.2	2
208	Biological Effects of COMT Haplotypes and Psychosis Risk in 22q11.2 Deletion Syndrome. Biological Psychiatry, 2014, 75, 406-413.	1.3	63
209	The Beneficial Effect of Trazodone Treatment on Escitalopram-Associated Nocturnal Bruxism. Journal of Clinical Psychopharmacology, 2014, 34, 662.	1.4	9
210	Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination. Psychopharmacology, 2013, 226, 615-622.	3.1	61
211	Mental disorders in primary care in Israel: prevalence and risk factors. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 1539-1554.	3.1	12
212	In vitro catabolic effect of protoporphyrin IX in human osteoblast-like cells: possible role of the 18 kDa mitochondrial translocator protein. Journal of Bioenergetics and Biomembranes, 2013, 45, 333-341.	2.3	15
213	Neuroprotective and procognitive effects of sertraline: In vitro and in vivo studies. Neuroscience Letters, 2013, 550, 93-97.	2.1	26
214	Association between a common CYP17A1 haplotype and anxiety in female anorexia nervosa. Archives of Women's Mental Health, 2013, 16, 423-428.	2.6	2
215	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. American Journal of Human Genetics, 2013, 92, 439-447.	6.2	53
216	Executive attention deficits in schizophrenia: Putative mandatory and differential cognitive pathology domains in medicated schizophrenia patients. Psychiatry Research, 2013, 209, 1-8.	3.3	14

#	Article	IF	CITATIONS
217	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. American Journal of Human Genetics, 2013, 92, 637.	6.2	1
218	Additive Effects of 5-HTTLPR (Serotonin Transporter) and Tryptophan Hydroxylase 2 G-703T Gene Polymorphisms on the Clinical Response to Citalopram among Children and Adolescents with Depression and Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 117-122.	1.3	23
219	The Factors Influencing Decision Making on Children's Psychiatric Hospitalization: A Retrospective Chart Review. Community Mental Health Journal, 2013, 49, 73-78.	2.0	9
220	Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro. European Neuropsychopharmacology, 2013, 23, 1115-1123.	0.7	13
221	Neonatal stress modulates sickness behavior: Role for proinflammatory cytokines. Journal of Neuroimmunology, 2013, 257, 59-66.	2.3	28
222	Schizophrenia-like neurophysiological abnormalities in 22q11.2 deletion syndrome and their association to COMT and PRODH genotypes. Journal of Psychiatric Research, 2013, 47, 1623-1629.	3.1	37
223	Acute manic episode is associated with an increased risk of lower limb edema. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 47, 99-103.	4.8	4
224	The Effects of Reboxetine Treatment on Depression-like Behavior, Brain Neurotrophins, and ERK Expression in Rats Exposed to Chronic Mild Stress. Journal of Molecular Neuroscience, 2013, 50, 88-97.	2.3	38
225	Risk Factors and the Evolution of Psychosis in 22q11.2 Deletion Syndrome: A Longitudinal 2-Site Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 1192-1203.e3.	0.5	108
226	Escitalopram in the treatment of patients with schizophrenia and obsessive–compulsive disorder. International Clinical Psychopharmacology, 2013, 28, 96-98.	1.7	31
227	Attention-Deficit/Hyperactivity Disorder and Comorbid Subsyndromal Depression. Clinical Neuropharmacology, 2013, 36, 141-145.	0.7	16
228	Reboxetine Treatment for Autistic Spectrum Disorder of Pediatric Patients With Depressive and Inattentive/Hyperactive Symptoms. Clinical Neuropharmacology, 2013, 36, 37-41.	0.7	22
229	Alcohol-Metabolizing Genes and Alcohol Phenotypes in an Israeli Household Sample. Alcoholism: Clinical and Experimental Research, 2013, 37, 1872-1881.	2.4	16
230	High Circulatory Titer of Platelet-Associated Autoantibodies in Childhood Onset Schizophrenia and Its Diagnostic Implications. Neuropsychobiology, 2013, 68, 124-127.	1.9	2
231	Suicidal Thoughts Are Associated with Platelet Counts in Adolescent Inpatients. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 49-53.	1.3	8
232	Hematological and Cardiometabolic Safety of Clozapine in the Treatment of Very Early Onset Schizophrenia: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 516-521.	1.3	11
233	Interactions between risky decisions, impulsiveness and smoking in young tattooed women. BMC Psychiatry, 2013, 13, 278.	2.6	17
234	miR-192 Directly Binds and Regulates Dicer1 Expression in Neuroblastoma. PLoS ONE, 2013, 8, e78713.	2.5	37

#	Article	IF	CITATIONS
235	Rivastigmine Treatment for the Prevention of Electroconvulsive Therapy–Induced Memory Deficits in Patients With Schizophrenia. Clinical Neuropharmacology, 2012, 35, 161-164.	0.7	14
236	Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients. International Clinical Psychopharmacology, 2012, 27, 159-164.	1.7	7
237	Antidepressant Treatment for Acute Bipolar Depression: An Update. Depression Research and Treatment, 2012, 2012, 1-10.	1.3	17
238	Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?. International Clinical Psychopharmacology, 2012, 27, 134-141.	1.7	2
239	Alcohol Use Disorders and Perceived Drinking Norms: Ethnic Differences in Israeli Adults. Journal of Studies on Alcohol and Drugs, 2012, 73, 981-990.	1.0	22
240	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of Extended-Release Metadoxine in Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2012, 73, 1517-1523.	2.2	23
241	The feasibility and safety of S-adenosyl-l-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. Journal of Neural Transmission, 2012, 119, 1417-1423.	2.8	12
242	Olfactory function and alternation learning in eating disorders. European Neuropsychopharmacology, 2012, 22, 615-624.	0.7	15
243	Theory of mind, severity of autistic symptoms and parental correlates in children and adolescents with Asperger syndrome. Psychiatry Research, 2012, 197, 85-89.	3.3	26
244	Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder. Psychiatry Research, 2012, 197, 19-22.	3.3	39
245	The influence of DHEA pretreatment on prepulse inhibition and the HPA-axis stress response in rat offspring exposed prenatally to polyriboinosinic–polyribocytidylic-acid (PIC). Neuroscience Letters, 2012, 521, 6-10.	2.1	2
246	Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients. Comprehensive Psychiatry, 2012, 53, 269-274.	3.1	30
247	Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Comprehensive Psychiatry, 2012, 53, 480-483.	3.1	101
248	Genotype-phenotype correlation in 22q11.2 deletion syndrome. BMC Medical Genetics, 2012, 13, 122.	2.1	83
249	Are Names of Children with Attention Deficit Hyperactivity Disorder More â€~Hyperactive'?. Psychopathology, 2012, 45, 215-219.	1.5	2
250	Perfectionism, narcissism, and depression in suicidal and nonsuicidal adolescent inpatients. Comprehensive Psychiatry, 2012, 53, 746-752.	3.1	29
251	Handshaking as a measure of social responsiveness in patients with autistic spectrum disorder. Comprehensive Psychiatry, 2012, 53, 805-808.	3.1	3
252	Outcomes of compulsorily admitted schizophrenia patients who agreed or disagreed to prolong their hospitalization. Comprehensive Psychiatry, 2012, 53, 995-999.	3.1	5

#	Article	IF	Citations
253	Emerging Association Between Addictive Gaming and Attention-Deficit/Hyperactivity Disorder. Current Psychiatry Reports, 2012, 14, 590-597.	4.5	78
254	Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. Journal of Affective Disorders, 2012, 136, 99-103.	4.1	81
255	Phenotypic psychiatric characterization of children with Williams syndrome and response of those with ADHD to methylphenidate treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 1598, 13-20.	1.7	32
256	Peptide-binding GRP78 protects neurons from hypoxia-induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 278-288.	4.9	35
257	Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment. European Child and Adolescent Psychiatry, 2012, 21, 75-78.	4.7	4
258	Platelet Vesicular Monoamine Transporter 2 Density in the Disruptive Behavior Disorders. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 341-344.	1.3	8
259	The Effect of Methylphenidate on Prefrontal Cognitive Functioning, Inattention, and Hyperactivity in Velocardiofacial Syndrome. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 589-595.	1.3	40
260	Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study. Schizophrenia Research, 2011, 130, 176-181.	2.0	57
261	GnRH-agonist induced depressive and anxiety symptoms during in vitro fertilization–embryo transfer cycles. Fertility and Sterility, 2011, 95, 307-309.	1.0	25
262	Methadone maintenance and cancer risk: An Israeli case registry study. Drug and Alcohol Dependence, 2011, 119, 88-92.	3.2	18
263	When Does It End? Attention-Deficit/Hyperactivity Disorder in the Middle Aged and Older Populations. Clinical Neuropharmacology, 2011, 34, 148-154.	0.7	41
264	Effectiveness and Safety of Citalopram in Hospitalized Adolescents With Major Depression. Clinical Neuropharmacology, 2011, 34, 182-185.	0.7	4
265	Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to I-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients.  Clinical Neuropharmacology, 2011, 34, 155-160.	0.7	24
266	Methylphenidate Treatment in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder and Comorbid Trichotillomania. Clinical Neuropharmacology, 2011, 34, 108-110.	0.7	20
267	Mirtazapine – A Multifunctional Drug: <i>Low Dose for Akathisia</i> . CNS Spectrums, 2011, 16, 63-63.	1.2	6
268	Nicotine dependence, abuse and craving: dimensionality in an Israeli sample. Addiction, 2011, 106, 1675-1686.	3.3	34
269	Gonadal steroids and affective symptoms during in vitro fertilization: Implication for reproductive mood disorders. Psychoneuroendocrinology, 2011, 36, 790-796.	2.7	15
270	Predictors of clozapine discontinuation in patients with schizophrenia. International Clinical Psychopharmacology, 2011, 26, 311-315.	1.7	38

#	Article	IF	Citations
271	In vitro mitochondrial effects of PK 11195, a synthetic translocator protein 18ÂkDa (TSPO) ligand, in human osteoblast-like cells. Journal of Bioenergetics and Biomembranes, 2011, 43, 739-746.	2.3	16
272	Altered affinity of the platelet vesicular monoamine transporter 2 to dihydrotetrabenazine in children with major depression. Journal of Neural Transmission, 2011, 118, 1383-1387.	2.8	4
273	Monitoring of Circadian Rhythms of Heart Rate, Locomotor Activity, and Temperature for Diagnosis and Evaluation of Response to Treatment in an Animal Model of Depression. Journal of Molecular Neuroscience, 2011, 43, 303-308.	2.3	7
274	The Effects of Fluoxetine Treatment in a Chronic Mild Stress Rat Model on Depression-Related Behavior, Brain Neurotrophins and ERK Expression. Journal of Molecular Neuroscience, 2011, 45, 246-255.	2.3	106
275	Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: A multi-center study. World Journal of Biological Psychiatry, 2011, 12, 33-41.	2.6	62
276	Low-Dose Quetiapine for Adolescents With Autistic Spectrum Disorder and Aggressive Behavior. Clinical Neuropharmacology, 2011, 34, 216-219.	0.7	52
277	Level of training of nursing staff and the autonomy given to psychiatric inpatients: a multicenter study. International Journal of Adolescent Medicine and Health, 2011, 23, 45-50.	1.3	1
278	Cognitive Behavior Therapy for Social Phobia in Large Groups. International Journal of Cognitive Therapy, 2011, 4, 92-103.	2.2	9
279	The Immunomodulatory Effect of the Antidepressant Sertraline in an Experimental Autoimmune Encephalomyelitis Mouse Model of Multiple Sclerosis. NeuroImmunoModulation, 2011, 18, 117-122.	1.8	48
280	Level of Function at Discharge as a Predictor of Readmission Among Inpatients With Schizophrenia. American Journal of Occupational Therapy, 2011, 65, 314-319.	0.3	10
281	Trazodone for the Treatment of Neuroleptic-Induced Acute Akathisia. Clinical Neuropharmacology, 2010, 33, 219-222.	0.7	37
282	Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. Journal of Neural Transmission, 2010, 117, 139-145.	2.8	25
283	Lack of modulatory effect of short-term repeated electroconvulsive therapy on platelet vesicular monoamine transporter 2 (VMAT2) in depressed patients. Journal of Neural Transmission, 2010, 117, 881-885.	2.8	3
284	Stroop performance in major depression: Selective attention impairment or psychomotor slowness?. Journal of Affective Disorders, 2010, 122, 167-173.	4.1	43
285	The role of dehydroepiandrosterone (DHEA) in drug-seeking behavior. Neuroscience and Biobehavioral Reviews, 2010, 35, 303-314.	6.1	32
286	Alteration learning in social anxiety disorder: An fMRI study. World Journal of Biological Psychiatry, 2010, 11, 352-356.	2.6	4
287	Stability of Schizoaffective Disorder in Correlation with Duration of Follow-Up: Retrospective Analysis. Psychopathology, 2010, 43, 285-291.	1.5	6
288	In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells. International Journal of Oncology, 2010, 37, 1043-51.	3.3	20

#	Article	IF	CITATIONS
289	WORKING MEMORY IMPAIRMENTS IN SCHIZOPHRENIA AS VALID PREDICTORS OF ILNESS SEVERITY AND FUNCTIONAL OUTCOME. Schizophrenia Research, 2010, 117, 300.	2.0	0
290	Alterations in QT dispersion in the surface electrocardiogram of female adolescent inpatients diagnosed with bulimia nervosa. Comprehensive Psychiatry, 2010, 51, 406-411.	3.1	10
291	Fear Thou Not: Activity of Frontal and Temporal Circuits in Moments of Real-Life Courage. Neuron, 2010, 66, 949-962.	8.1	95
292	Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychiatry, 2010, 71, 1351-1362.	2.2	77
293	Velocardiofacial Syndrome. Journal of Mental Health Research in Intellectual Disabilities, 2009, 2, 149-167.	2.0	53
294	Blind Verification of Elevated Platelet Autoantibodies in Serum of Schizophrenic Patients – Part II: Adult Subjects. Neuropsychobiology, 2009, 60, 49-54.	1.9	6
295	Blind Verification of Elevated Platelet Autoantibodies in Serum of Schizophrenic Patients – Part I: Young Subjects. Neuropsychobiology, 2009, 60, 44-48.	1.9	6
296	Effect of Exposure to Selective Serotonin Reuptake Inhibitors In Utero on Fetal Growth: Potential Role for the IGF-I and HPA Axes. Pediatric Research, 2009, 65, 236-241.	2.3	66
297	DHEA Lessens Depressive-Like Behavior via GABA-ergic Modulation of the Mesolimbic System. Neuropsychopharmacology, 2009, 34, 577-584.	5.4	58
298	Altered thermoregulation in ambulatory schizophrenia patients: A naturalistic study. World Journal of Biological Psychiatry, 2009, 10, 163-170.	2.6	19
299	The risk for cancer among patients with schizoaffective disorders. Journal of Affective Disorders, 2009, 114, 316-320.	4.1	16
300	Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy. Depression and Anxiety, 2009, 26, 289-300.	4.1	47
301	An integrative quantitative model of factors influencing the course of anorexia nervosa over time. International Journal of Eating Disorders, 2009, 42, 306-317.	4.0	73
302	Differences in audiovisual integration, as measured by McGurk phenomenon, among adult and adolescent patients with schizophrenia and age-matched healthy control groups. Comprehensive Psychiatry, 2009, 50, 186-192.	3.1	78
303	Neuropsychological mechanisms of Digit Symbol Substitution Test impairment in Asperger Disorder. Psychiatry Research, 2009, 166, 35-45.	3.3	26
304	Priapism as an unusual manifestation of catatonia: A case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 570.	4.8	1
305	Platelet poor plasma serotonin level in delinquent adolescents diagnosed with conduct disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1223-1225.	4.8	12
306	Factors Determining Satisfaction in Psychiatry Training in Israel. Academic Psychiatry, 2009, 33, 169-173.	0.9	16

#	Article	IF	Citations
307	Î <sup>3</sup> -Aminobutyric Acid Amides of Nortriptyline and Fluoxetine Display Improved Pain Suppressing Activity. Journal of Medicinal Chemistry, 2009, 52, 3010-3017.	6.4	13
308	Early Repolarization in Young Children with Attention-Deficit/Hyperactivity Disorder Versus Normal Controls: A Retrospective Preliminary Chart Review Study. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 731-735.	1.3	13
309	BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. European Neuropsychopharmacology, 2009, 19, 1-13.	0.7	32
310	Improvement of aggressive behavior and quality of life impairment following S-Adenosyl-Methionine (SAM-e) augmentation in schizophrenia. European Neuropsychopharmacology, 2009, 19, 14-22.	0.7	45
311	Neurosteroid blood levels in delinquent adolescent boys with conduct disorder. European Neuropsychopharmacology, 2009, 19, 49-52.	0.7	24
312	Serum creatine kinase activity differentiates alcohol syndromes of dependence, withdrawal and delirium tremens. European Neuropsychopharmacology, 2009, 19, 92-96.	0.7	11
313	Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. European Neuropsychopharmacology, 2009, 19, 476-482.	0.7	29
314	DHEA and DHEA-S levels in hospitalized adolescents with first-episode schizophrenia and conduct disorder: A comparison study. European Neuropsychopharmacology, 2009, 19, 499-503.	0.7	11
315	Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. European Neuropsychopharmacology, 2009, 19, 654-658.	0.7	11
316	Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro. European Neuropsychopharmacology, 2009, 19, 726-734.	0.7	33
317	Attention-Deficit Hyperactivity Disorder, Methylphenidate, and Primary Encopresis. Psychosomatics, 2009, 50, 178.	2.5	18
318	Psychiatric Disorders and Intellectual Functioning Throughout Development in Velocardiofacial (22q11.2 Deletion) Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1060-1068.	0.5	253
319	Efficacy of Reboxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Boys With Intolerance to Methylphenidate. Clinical Neuropharmacology, 2009, 32, 179-182.	0.7	12
320	Influence of Methylphenidate Treatment on Smoking Behavior in Adolescent Girls With Attention-Deficit/Hyperactivity and Borderline Personality Disorders. Clinical Neuropharmacology, 2009, 32, 239-242.	0.7	5
321	Effect of Implementing Dental Services in Israeli Psychiatric Hospitals on the Oral and Dental Health of Inpatients. Psychiatric Services, 2009, 60, 799-803.	2.0	25
322	$\hat{l}^2$ -Adrenergic Antagonists for the Treatment of Clozapine-Induced Sinus Tachycardia. Clinical Neuropharmacology, 2009, 32, 290-292.	0.7	21
323	Schizophrenia Endophenotypes as Treatment Targets. , 2009, , 113-122.		1
324	Objective Versus Subjective Assessment of Methylphenidate Response. Child Psychiatry and Human Development, 2008, 39, 273-282.	1.9	15

#	Article	IF	CITATIONS
325	Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol. Journal of Neural Transmission, 2008, 115, 1563-1571.	2.8	7
326	Enhanced cancer risk among patients with bipolar disorder. Journal of Affective Disorders, 2008, 108, 43-48.	4.1	53
327	Does a Clerkship in Psychiatry Contribute to Changing Medical Students' Attitudes Towards Psychiatry?. Academic Psychiatry, 2008, 32, 147-150.	0.9	51
328	Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: Possible relevance to depression and hyperactive-immune disorders. International Immunopharmacology, 2008, 8, 526-533.	3.8	35
329	Neuroprotective effect of Ro5-4864 following brain injury. Experimental Neurology, 2008, 214, 201-208.	4.1	41
330	Sense of coherence among delusional patients: prediction of remission and risk of relapse. Comprehensive Psychiatry, 2008, 49, 288-296.	3.1	26
331	The influence of clozapine treatment and other antipsychotics on the 18ÂkDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. European Neuropsychopharmacology, 2008, 18, 24-33.	0.7	31
332	Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. European Neuropsychopharmacology, 2008, 18, 117-121.	0.7	53
333	Relationship between antidepressants and IGF-1 system in the brain: Possible role in cognition. European Neuropsychopharmacology, 2008, 18, 431-438.	0.7	35
334	The possible involvement of metabotropic glutamate receptors in schizophrenia. European Neuropsychopharmacology, 2008, 18, 395-405.	0.7	46
335	The effect of DHEA complementary treatment on heroin addicts participating in a rehabilitation program: A preliminary study. European Neuropsychopharmacology, 2008, 18, 406-413.	0.7	9
336	In vivo occipital–frontal temperature-gradient in schizophrenia patients and its possible association with psychopathology: A magnetic resonance spectroscopy study. European Neuropsychopharmacology, 2008, 18, 557-564.	0.7	11
337	A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects. Journal of Medicinal Chemistry, 2008, 51, 2858-2862.	6.4	24
338	Multi-modal weight control intervention for people with persistent mental disorders Psychiatric Rehabilitation Journal, 2008, 31, 194-200.	1.1	53
339	Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. International Journal of Neuropsychopharmacology, 2008, 11, 351-63.	2.1	41
340	The Impact of Mental Illness on Sexual Dysfunction. , 2008, 29, 89-106.		147
341	Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics, 2008, 9, 1725-1736.	1.3	22
342	Itching in the Psychiatric Ward. Acta Dermato-Venereologica, 2008, 88, 128-131.	1.3	55

#	Article	IF	Citations
343	Aripiprazole's Receptor Pharmacology and Extrapyramidal Side Effects. American Journal of Psychiatry, 2008, 165, 398-398.	7.2	14
344	Ziprasidone: clinical properties and therapeutic promise. Future Neurology, 2008, 3, 19-27.	0.5	0
345	Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. International Clinical Psychopharmacology, 2008, 23, 228-231.	1.7	30
346	The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line. Pharmacogenetics and Genomics, 2008, 18, 977-988.	1.5	40
347	Hormonal Response to Dehydroepiandrosterone Administration in Schizophrenia. Journal of Clinical Psychopharmacology, 2008, 28, 456-459.	1.4	11
348	Dehydroepiandrosterone and Pregnenolone Alterations in Schizophrenia., 2008,, 251-297.		5
349	The Role of Neurosteroids in Development of Pediatric Psychopathology. , 2008, , 539-553.		0
350	Neurosteroid Derangement in Women Diagnosed with Eating Disorders. , 2008, , 493-507.		1
351	Sildenafil citrate in the treatment of sexual dysfunction and its effect on quality of life in alcohol dependent men: preliminary findings. Alcohol and Alcoholism, 2007, 42, 340-346.	1.6	13
352	QT Interval and Dispersion in Very Young Children Treated with Antipsychotic Drugs: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 187-194.	1.3	20
353	Reboxetine Maintenance Treatment in Children with Attention-Deficit/Hyperactivity Disorder: A Long-Term Follow-Up Study. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 803-812.	1.3	16
354	Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness and Side Effects in Children with Depression and/or Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 741-750.	1.3	66
355	Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone. International Clinical Psychopharmacology, 2007, 22, 192-196.	1.7	6
356	Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. International Journal of Neuropsychopharmacology, 2007, 10, 301.	2.1	54
357	Neurological Soft Signs in Schizophrenia Patients With Obsessive-Compulsive Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 145-150.	1.8	29
358	Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 378-382.	4.8	32
359	A 10-year retrospective study of inpatient adolescents with schizophrenia/schizoaffective disorder and substance use. Comprehensive Psychiatry, 2007, 48, 1-7.	3.1	15
360	Alterations in QT dispersion in the surface electrocardiogram of female adolescents diagnosed with restricting-type anorexia nervosa. Journal of Psychosomatic Research, 2007, 62, 469-472.	2.6	61

#	Article	IF	Citations
361	Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Molecular and Cellular Neurosciences, 2007, 36, 305-312.	2.2	50
362	Psychological and cytokine changes in children and adolescents undergoing hematopoietic stem cell transplantation. European Neuropsychopharmacology, 2007, 17, 58-63.	0.7	4
363	Neurosteroids in child and adolescent psychopathology. European Neuropsychopharmacology, 2007, 17, 157-164.	0.7	26
364	Association of the serotonin transporter promotor polymorphism with suicide attempters with a high medical damage. European Neuropsychopharmacology, 2007, 17, 230-233.	0.7	38
365	Serum creatine kinase level in unmedicated nonpsychotic, psychotic, bipolar and schizoaffective depressed patients. European Neuropsychopharmacology, 2007, 17, 194-198.	0.7	25
366	State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients. European Neuropsychopharmacology, 2007, 17, 257-264.	0.7	37
367	Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. European Neuropsychopharmacology, 2007, 17, 358-365.	0.7	50
368	A significant correlation between ward temperature and the severity of symptoms in schizophrenia inpatients $\hat{a} \in \mathbb{Z}$ A longitudinal study. European Neuropsychopharmacology, 2007, 17, 478-482.	0.7	12
369	Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients. European Neuropsychopharmacology, 2007, 17, 523-526.	0.7	10
370	Circulatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients. European Neuropsychopharmacology, 2007, 17, 541-545.	0.7	12
371	Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. European Neuropsychopharmacology, 2007, 17, 774-780.	0.7	91
372	CK levels in unmedicated bipolar patients. European Neuropsychopharmacology, 2007, 17, 763-767.	0.7	16
373	Demographic and clinical characteristics of motor vehicle accident victims in the community general health outpatient clinic: a comparison of PTSD and non-PTSD subjects. Depression and Anxiety, 2007, 24, 244-250.	4.1	55
374	Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial. Psychoneuroendocrinology, 2007, 32, 96-105.	2.7	77
375	Dual contribution of NR2B subunit of NMDA receptor and SK3 Ca2+-activated K+ channel to genetic predisposition to anorexia nervosa. Journal of Psychiatric Research, 2007, 41, 160-167.	3.1	24
376	Risk of readmission in compulsorily and voluntarily admitted patients. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 916-922.	3.1	18
377	Thyroxine-Triiodothyronine Combination TherapyVersusThyroxine Monotherapy for Clinical Hypothyroidism: Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2592-2599.	3.6	266
378	Substance Use, Suicidality, and Adolescent-Onset Schizophrenia: An Israeli 10-Year Retrospective Study. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 767-775.	1.3	19

#	Article	IF	Citations
379	Plasma serotonin levels and suicidal behavior in adolescents. European Neuropsychopharmacology, 2006, 16, 49-57.	0.7	54
380	Serotonin uptake to lymphocytes of patients with social phobia compared to normal individuals. European Neuropsychopharmacology, 2006, 16, 19-23.	0.7	2
381	Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. European Neuropsychopharmacology, 2006, 16, 107-113.	0.7	102
382	Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. European Neuropsychopharmacology, 2006, 16, 137-146.	0.7	51
383	The relevance of neurosteroids to clinical psychiatry: From the laboratory to the bedside. European Neuropsychopharmacology, 2006, 16, 155-169.	0.7	93
384	Dehydroepiandrosterone (DHEA) attenuates cocaine-seeking behavior in the self-administration model in rats. European Neuropsychopharmacology, 2006, 16, 329-339.	0.7	36
385	Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals. European Neuropsychopharmacology, 2006, 16, 429-436.	0.7	14
386	Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients. European Neuropsychopharmacology, 2006, 16, 572-579.	0.7	19
387	Electroconvulsive Therapy and Transcranial Magnetic Stimulation: Can They be Considered Valid Modalities in the Treatment of Pediatric Mood Disorders?. Child and Adolescent Psychiatric Clinics of North America, 2006, 15, 1035-1056.	1.9	11
388	Two Different Putative Genetic Animal Models of Childhood Depression. Biological Psychiatry, 2006, 59, 17-23.	1.3	75
389	Low-Dose Mirtazapine: A New Option in the Treatment of Antipsychotic-Induced Akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial. Biological Psychiatry, 2006, 59, 1071-1077.	1.3	107
390	Obstetric complications in individuals diagnosed with autism and in healthy controls. Comprehensive Psychiatry, 2006, 47, 69-75.	3.1	62
391	Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends in Pharmacological Sciences, 2006, 27, 402-409.	8.7	1,237
392	A Six-Month Outcome of Long-Stay Inpatients Resettled in a Hostel Psychiatric Rehabilitation Journal, 2006, 30, 89-95.	1.1	7
393	Preferential Aggregation of Obsessive—Compulsive Spectrum Disorders in Schizophrenia Patients with Obsessive—Compulsive Disorder. Canadian Journal of Psychiatry, 2006, 51, 746-754.	1.9	42
394	Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-related Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology, 2006, 26, 152-156.	1.4	26
395	Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. International Clinical Psychopharmacology, 2006, 21, 99-103.	1.7	58
396	Impact of Gastric Banding on Plasma Adiponectin Levels. Obesity Surgery, 2006, 16, 1057-1061.	2.1	20

#	Article	IF	Citations
397	Obsessive–compulsive disorder in bipolar disorder patients with first manic episode. Journal of Affective Disorders, 2006, 94, 151-156.	4.1	15
398	The protective effect of frontal cortex dehydroepiandrosterone in anxiety and depressive models in mice. Pharmacology Biochemistry and Behavior, 2006, 85, 415-421.	2.9	29
399	Clinical characteristics of inpatient adolescents with severe obsessive–compulsive disorder. Depression and Anxiety, 2006, 23, 62-70.	4.1	25
400	Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12â€week observational study. Human Psychopharmacology, 2006, 21, 235-243.	1.5	26
401	Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncology Reports, 2006, 15, 107.	2.6	26
402	DHEA, a Neurosteroid, Decreases Cocaine Self-Administration and Reinstatement of Cocaine-Seeking Behavior in Rats. Neuropsychopharmacology, 2006, 31, 2231-2236.	5 <b>.</b> 4	43
403	The use of illicit substances in adolescent schizophrenia inpatients. International Journal of Adolescent Medicine and Health, 2006, 18, 643-8.	1.3	3
404	The Child in the Family of a Drug-Using Father: Attachment Styles and Family Characteristics. Journal of Social Work Practice in the Addictions, 2006, 6, 89-111.	0.7	8
405	An Open-Label Randomized Comparison of Olanzapine Versus Risperidone in the Treatment of Childhood-Onset Schizophrenia. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 393-403.	1.3	51
406	Corneal temperature in schizophrenia patients. International Journal of Neuropsychopharmacology, 2005, 8, 537.	2.1	14
407	Hormonal Profile Effects Following Dehydroepiandrosterone (DHEA) Administration to Schizophrenic Patients. Clinical Neuropharmacology, 2005, 28, 265-269.	0.7	24
408	The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. International Clinical Psychopharmacology, 2005, 20, 101-103.	1.7	51
409	The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open label preliminary study. International Clinical Psychopharmacology, 2005, 20, 23-25.	1.7	8
410	Impact of Gastric Banding on Plasma Ghrelin, Growth Hormone, Cortisol, DHEA and DHEA-S Levels. Obesity Surgery, 2005, 15, 1118-1123.	2.1	35
411	The Relationship between BMI, Plasma Leptin, Insulin and Proinsulin Before and After Laparoscopic Adjustable Gastric Banding. Obesity Surgery, 2005, 15, 1456-1462.	2.1	25
412	Differential Induction of Apoptosis by Antidepressants in Glioma and Neuroblastoma Cell Lines: Evidence for p-c-Jun, Cytochrome c, and Caspase-3 Involvement. Journal of Molecular Neuroscience, 2005, 27, 029-042.	2.3	143
413	Involvement of prostaglandins in an animal model of Shigella-related seizures. Journal of Neuroimmunology, 2005, 168, 34-39.	2.3	11
414	New drug targets for depression and anxiety: Is the peptides era arriving?. Drug Development Research, 2005, 65, 93-96.	2.9	2

#	Article	IF	Citations
415	Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 31-36.	1.7	39
416	Haplotype analysis of the COMT-ARVCF gene region in Israeli anorexia nervosa family trios. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 139B, 45-50.	1.7	18
417	Life events and suicidality in adolescents with schizophrenia. European Child and Adolescent Psychiatry, 2005, 14, 454-460.	4.7	19
418	Cortisol/Dehydroepiandrosterone Ratio and Responses to Antipsychotic Treatment in Schizophrenia. Neuropsychopharmacology, 2005, 30, 1913-1922.	5.4	51
419	Memantine for Treatment-Resistant OCD. American Journal of Psychiatry, 2005, 162, 2191-a-2192.	7.2	105
420	A Possible Antienuretic Effect of Reboxetine in Children and Adolescents with Attention Deficit/Hyperactivity Disorder: Case Series. Neuropsychobiology, 2005, 51, 239-242.	1.9	14
421	Family-based association study of 5-HT2A receptor T102C polymorphism and suicidal behavior in Ashkenazi inpatient adolescents. International Journal of Adolescent Medicine and Health, 2005, 17, 231-8.	1.3	16
422	Expressed Emotion: Relevance to Rehospitalization in Schizophrenia Over 7 Years. Schizophrenia Bulletin, 2005, 31, 751-758.	4.3	67
423	Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. International Journal of Oncology, 2005, 27, 1097.	3.3	9
424	Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder. European Neuropsychopharmacology, 2005, 15, 159-162.	0.7	15
425	Repeated swim stress leads to down-regulation of vesicular monoamine transporter 2 in rat brain nucleus accumbens and striatum. European Neuropsychopharmacology, 2005, 15, 199-201.	0.7	20
426	The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression. European Neuropsychopharmacology, 2005, 15, 253-262.	0.7	31
427	Decreased platelet vesicular monoamine transporter density in habitual smokers. European Neuropsychopharmacology, 2005, 15, 235-238.	0.7	16
428	Lowered DHEA-S plasma levels in adult individuals with autistic disorder. European Neuropsychopharmacology, 2005, 15, 305-309.	0.7	50
429	The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. European Neuropsychopharmacology, 2005, 15, 319-329.	0.7	172
430	Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients. European Neuropsychopharmacology, 2005, 15, 557-561.	0.7	11
431	Effects of climate on admission rates of schizophrenia patients to psychiatric hospitals. European Psychiatry, 2005, 20, 61-64.	0.2	81
432	Pilot Study: Fluvoxamine Treatment for Depression and Anxiety Disorders in Children and Adolescents with Cancer. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 1258-1262.	0.5	48

#	Article	IF	CITATIONS
433	Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 428-433.	0.5	34
434	Reboxetine as an Optional Treatment for Hyperkinetic Conduct Disorder: A Prospective Open-Label Trial. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 259-269.	1.3	24
435	The Peripheral-Type Benzodiazepine Receptor and Tumorigenicity:  Isoquinoline Binding Protein (IBP) Antisense Knockdown in the C6 Glioma Cell Line. Biochemistry, 2005, 44, 9924-9935.	2.5	66
436	Is brain dehydroepiandrosterone synthesis modulated by free radicals in mice?. Neuroscience Letters, 2005, 377, 130-135.	2.1	15
437	The effect of $17\hat{l}^2$ estradiol withdrawal on the level of brain and peripheral neurosteroids in ovarectomized rats. Neuroscience Letters, 2005, 384, 156-161.	2.1	19
438	Impaired procedural learning in obsessive?compulsive disorder and Parkinson's disease, but not in major depressive disorder. Behavioural Brain Research, 2005, 157, 253-263.	2.2	56
439	Platelet vesicular monoamine transporter density in untreated patients diagnosed with social phobia. Psychiatry Research, 2005, 136, 247-250.	3.3	3
440	Involvement of GABAA receptor modulating neuroactive steroids in patients with social phobia. Psychiatry Research, 2005, 137, 131-136.	3.3	21
441	Cancer in schizophrenia: is the risk higher or lower?. Schizophrenia Research, 2005, 73, 333-341.	2.0	140
442	Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial. Schizophrenia Research, 2005, 79, 251-256.	2.0	54
443	Ondansetron Treatment in Tourette's Disorder. Journal of Clinical Psychiatry, 2005, 66, 499-503.	2.2	52
444	The Influence of Parturition on the Level and Synthesis of Sulfated and Free Neurosteroids in Rats. Neuropsychobiology, 2004, 49, 17-23.	1.9	10
445	Low Platelet-Poor Plasma Levels of Serotonin in Adult Autistic Patients. Neuropsychobiology, 2004, 50, 157-160.	1.9	35
446	Personalized psychiatry: a realistic goal. Pharmacogenomics, 2004, 5, 213-217.	1.3	20
447	Complexity of the dynamic QT variability and RR variability in patients with acute anterior wall myocardial infarction. Journal of Electrocardiology, 2004, 37, 173-179.	0.9	14
448	Involvement of the neuropeptide corticotropin-releasing hormone in an animal model of Shigella-related seizures. Journal of Neuroimmunology, 2004, 153, 36-39.	2.3	10
449	QT dispersion in patients with social phobia. Journal of Affective Disorders, 2004, 78, 21-26.	4.1	27
450	Electroconvulsive therapy in adolescent and adult psychiatric inpatientsâ€"a retrospective chart design. Journal of Affective Disorders, 2004, 82, 335-42.	4.1	18

#	Article	IF	Citations
451	Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines. Biochemical Pharmacology, 2004, 68, 689-698.	4.4	89
452	Influence of $17\hat{l}^2$ -estradiol on the synthesis of reduced neurosteroids in the brain (in vivo) and in glioma cells (in vitro): possible relevance to mental disorders in women. Brain Research, 2004, 1020, 167-172.	2.2	16
453	Characterization of Phenothiazine-Induced Apoptosis in Neuroblastoma and Glioma Cell Lines: Clinical Relevance and Possible Application for Brain-Derived Tumors. Journal of Molecular Neuroscience, 2004, 22, 189-198.	2.3	80
454	Admission rates of bipolar depressed patients increase during spring/summer and correlate with maximal environmental temperature. Bipolar Disorders, 2004, 6, 90-93.	1.9	58
455	Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. American Journal of Medical Genetics Part A, 2004, 126B, 99-105.	2.4	130
456	CAG repeat polymorphism within the KCNN3 gene is a significant contributor to susceptibility to anorexia nervosa: A case-control study of female patients and several ethnic groups in the Israeli Jewish population. American Journal of Medical Genetics Part A, 2004, 131B, 76-80.	2.4	21
457	The utility of the Visual Analogue Scale for the assessment of depressive mood in cognitively impaired patients. International Journal of Geriatric Psychiatry, 2004, 19, 789-796.	2.7	25
458	Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Human Psychopharmacology, 2004, 19, 343-346.	1.5	35
459	Sexual Dimorphism in obsessive-compulsive disorder. World Journal of Biological Psychiatry, 2004, 5, 235-235.	2.6	1
460	Obsessive-Compulsive Disorder in Schizophrenia. CNS Drugs, 2004, 18, 989-1010.	5.9	133
461	Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. European Neuropsychopharmacology, 2004, 14, 237-243.	0.7	32
462	Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on $\hat{l}^2$ -catenin in mouse hippocampus. Biological Psychiatry, 2004, 55, 781-784.	1.3	269
463	Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophrenia Research, 2004, 71, 427-434.	2.0	85
464	Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents. Drug Safety, 2004, 27, 1135-1156.	3.2	63
465	Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. Psychiatry Research, 2004, 127, 227-235.	3.3	37
466	Psychosocial situations, quality of depression and schizophrenia in adolescents. Psychiatry Research, 2004, 129, 149-157.	3.3	9
467	Heart rate variability increases in elderly depressed patients who respond to electroconvulsive therapy. Journal of Psychosomatic Research, 2004, 56, 89-94.	2.6	28
468	Heart Rate Variability in Patients With Major Depression. Psychosomatics, 2004, 45, 129-134.	2.5	103

#	Article	IF	Citations
469	Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. European Neuropsychopharmacology, 2004, 14, 267-273.	0.7	125
470	The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology, 2004, 14, 332-336.	0.7	57
471	Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient. European Psychiatry, 2004, 19, 237-238.	0.2	12
472	D2 Antagonist Augmentation in Patients with a Partial Response to Atypical Antipsychotics. Canadian Journal of Psychiatry, 2004, 49, 281-282.	1.9	3
473	Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEA-S) levels. International Journal of Neuropsychopharmacology, 2004, 7, 71-75.	2.1	15
474	Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. International Clinical Psychopharmacology, 2004, 19, 23-26.	1.7	50
475	Dimensional complexity of the neuronal activity in a rat model of depression. NeuroReport, 2004, 15, 1983-1986.	1.2	10
476	An Open-Label Trial of Sildenafil Addition in Risperidone-Treated Male Schizophrenia Patients With Erectile Dysfunction. Journal of Clinical Psychiatry, 2004, 65, 97-103.	2.2	31
477	Musical Hallucinations: Prevalence in Psychotic and Nonpsychotic Outpatients. Journal of Clinical Psychiatry, 2004, 65, 191-197.	2.2	65
478	Beneficial Effects of Gonadotropin-Releasing Hormone Analogue Treatment on Positive and Negative Symptoms of Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 1020-1021.	2.2	2
479	A Case of Hyponatremia Associated With Escitalopram. Journal of Clinical Psychiatry, 2004, 65, 1722.	2.2	21
480	Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression. Brain Research, 2003, 965, 174-179.	2.2	40
481	Depression and suicidal behavior in adolescent inpatients with obsessive compulsive disorder. Journal of Affective Disorders, 2003, 75, 181-189.	4.1	53
482	Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients. Journal of Psychiatric Research, 2003, 37, 549-556.	3.1	40
483	The platelet-poor plasma 5-HT response to carbohydrate rich meal administration in adult autistic patients compared with normal controls. Human Psychopharmacology, 2003, 18, 395-399.	1.5	12
484	Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. European Neuropsychopharmacology, 2003, 13, 29-31.	0.7	30
485	Increased corneal temperature in drug-free male schizophrenia patients. European Neuropsychopharmacology, 2003, 13, 49-52.	0.7	22
486	Alternation learning in OCD/schizophrenia patients. European Neuropsychopharmacology, 2003, 13, 87-91.	0.7	30

#	Article	IF	CITATIONS
487	Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. European Neuropsychopharmacology, 2003, 13, 123-128.	0.7	70
488	DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European Neuropsychopharmacology, 2003, 13, 183-185.	0.7	40
489	Brain neurosteroid changes after paroxetine administration in mice. European Neuropsychopharmacology, 2003, 13, 327-332.	0.7	23
490	Comparison of ego defenses among physically abused children, neglected, and non-maltreated children. Comprehensive Psychiatry, 2003, 44, 388-395.	3.1	18
491	Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends in Pharmacological Sciences, 2003, 24, 122-125.	8.7	96
492	Neuroimaging communality between schizophrenia and obsessive compulsive disorder: A putative basis for schizo-obsessive disorder?. World Journal of Biological Psychiatry, 2003, 4, 129-134.	2.6	60
493	Bidirectional Concentration-Dependent Effects of Tumor Necrosis Factor Alpha in Shigella dysenteriae -Related Seizures. Infection and Immunity, 2003, 71, 2288-2291.	2.2	35
494	Lower Corneal Temperature in Neuroleptic-Treated vs. Drug-Free Schizophrenia Patients. Neuropsychobiology, 2003, 48, 1-4.	1.9	9
495	Platelet-Associated Antibodies Mediate Protective Autoimmune Response in Schizophrenia. Neuropsychobiology, 2003, 48, 41-46.	1.9	7
496	Three-Month Treatment Course of Methylphenidate Increases Plasma Levels of Dehydroepiandrosterone (DHEA) and Dehydroepiandrosterone-Sulfate (DHEA-S) in Attention Deficit Hyperactivity Disorder. Neuropsychobiology, 2003, 48, 111-115.	1.9	38
497	Olanzapine Treatment in Chronic Drug-Resistant Childhood-Onset Schizophrenia: An Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 2003, 13, 311-317.	1.3	42
498	Sildenafil for Selective Serotonin Reuptake Inhibitor-Induced Erectile Dysfunction in Elderly Male Depressed Patients. Journal of Sex and Marital Therapy, 2003, 29, 297-303.	1.5	11
499	Effectiveness, Safety, and Tolerability of Risperidone in Adolescents with Schizophrenia: An Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 2003, 13, 319-327.	1.3	47
500	Granulocytopenia associated with neuroleptic therapy in a patient with benign familial leukopenia. International Journal of Psychiatry in Clinical Practice, 2003, 7, 277-280.	2.4	1
501	Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia. Archives of General Psychiatry, 2003, 60, 133.	12.3	200
502	Plasma Testosterone Levels in Patients with Combat-Related Posttraumatic Stress Disorder. Neuropsychobiology, 2003, 47, 57-60.	1.9	20
503	Variability of Color Choice in the LÃ⅓scher Color Test—Sex Differences. Perceptual and Motor Skills, 2003, 97, 647-656.	1.3	4
504	Substantial increase in number and dosage of antipsychotics in non-responsive vs. responsive schizophrenia inpatients. International Journal of Psychiatry in Clinical Practice, 2003, 7, 53-57.	2.4	2

#	Article	IF	Citations
505	Efficacy of Low-Dose Mirtazapine in Neuroleptic-Induced Akathisia: A Double-Blind Randomized Placebo-Controlled Pilot Study. Journal of Clinical Psychopharmacology, 2003, 23, 305-308.	1.4	38
506	Precautionary measures reduce risk of definite neuroleptic malignant syndrome in newly typical neuroleptic-treated schizophrenia inpatients. International Clinical Psychopharmacology, 2003, 18, 147-149.	1.7	0
507	Title is missing!. Journal of Clinical Psychopharmacology, 2003, 23, 305-308.	1.4	20
508	Defense Mechanisms in a Community-Based Sample of Female Adolescents with Partial Eating Disorders. International Journal of Psychiatry in Medicine, 2003, 33, 343-355.	1.8	18
509	Amantadine as augmentation therapy in the management of treatment-resistant depression. International Clinical Psychopharmacology, 2003, 18, 93-96.	1.7	90
510	Beneficial Effect of Donepezil Augmentation for the Management of Comorbid Schizophrenia and Dementia. Clinical Neuropharmacology, 2003, 26, 12-17.	0.7	53
511	The Drug-User Husband and His Wife: Attachment Styles, Family Cohesion, and Adaptability. Substance Use and Misuse, 2003, 38, 271-292.	1.4	37
512	Treatment of Neuroleptic-Induced Akathisia With the 5-HT2A Antagonist Trazodone. Clinical Neuropharmacology, 2003, 26, 137-141.	0.7	27
513	Selegiline in the Treatment of Sexual Dysfunction in Schizophrenic Patients Maintained on Neuroleptics: A Pilot Study. Clinical Neuropharmacology, 2003, 26, 193-195.	0.7	23
514	Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 2003, 160, 297-302.	7.2	114
515	Olanzapine-Sertraline Combination in Schizophrenia With Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2003, 64, 611.	2.2	19
516	The Effects of Clozapine Versus Haloperidol on Measures of Impulsive Aggression and Suicidality in Chronic Schizophrenia Patients. Journal of Clinical Psychiatry, 2003, 64, 755-760.	2.2	60
517	Risperidone, but Not Olanzapine, Decreases Bone Mineral Density in Female Premenopausal Schizophrenia Patients. Journal of Clinical Psychiatry, 2003, 64, 761-766.	2.2	85
518	Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Velocardiofacial Syndrome. Journal of Clinical Psychiatry, 2003, 64, 1163-1169.	2.2	73
519	Comparison of Clinical Characteristics and Comorbidity in Schizophrenia Patients With and Without Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2003, 64, 1300-1307.	2.2	66
520	Safety and efficacy of long-term low-dose clozapine aftercare treatment in a patient with learning difficulties who suffered from neuroleptic malignant syndrome. International Journal of Psychiatry in Clinical Practice, 2002, 6, 121-123.	2.4	2
521	Head circumference and incident Alzheimer's disease: Modification by apolipoprotein E. Neurology, 2002, 58, 1440-1440.	1.1	6
522	Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine. American Journal of Psychiatry, 2002, 159, 1055-1057.	7.2	223

#	Article	IF	CITATIONS
523	Anticholinergic Burden and the Risk of Falls Among Elderly Psychiatric Inpatients: A 4-Year Case-Control Study. International Psychogeriatrics, 2002, 14, 307-310.	1.0	125
524	High Serum Creatinine Kinase Level: Possible Risk Factor for Neuroleptic Malignant Syndrome. Journal of Clinical Psychopharmacology, 2002, 22, 252-256.	1.4	39
525	Familial Expressed Emotion: Outcome and Course of Israeli Patients With Schizophrenia. Schizophrenia Bulletin, 2002, 28, 731-743.	4.3	30
526	Olanzapine-Induced Weight Gain in Patients With First-Episode Schizophrenia: A Double-Blind, Placebo-Controlled Study of Fluoxetine Addition. American Journal of Psychiatry, 2002, 159, 1058-1060.	7.2	89
527	Sildenafil Citrate for the Sexual Dysfunction in Antidepressant-Treated Male Patients with Posttraumatic Stress Disorder. Psychotherapy and Psychosomatics, 2002, 71, 173-176.	8.8	13
528	Serum Creatine Kinase Levels in Untreated Hospitalized Adolescents During Acute Psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 1045-1053.	0.5	14
529	An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophrenia. Biological Psychiatry, 2002, 51, 788-794.	1.3	34
530	Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2. European Neuropsychopharmacology, 2002, 12, 261-268.	0.7	26
531	Increased platelet vesicular monoamine transporter density in adult schizophrenia patients. European Neuropsychopharmacology, 2002, 12, 343-347.	0.7	24
532	Sexual Function and Behavior in Social Phobia. Journal of Clinical Psychiatry, 2002, 63, 874-879.	2.2	64
533	Seasonality of birth in patients with type 1 diabetes. Lancet, The, 2002, 359, 1247.	13.7	0
534	Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression. Psychiatry Research, 2002, 112, 251-256.	3.3	27
535	Individual and familial psychopathology among hospitalized minors at risk, juvenile delinquents, and psychiatric controls. International Journal of Law and Psychiatry, 2002, 25, 611-622.	0.9	2
536	The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns. Drug Discovery Today, 2002, 7, 403-406.	6.4	11
537	Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Human Psychopharmacology, 2002, 17, 181-185.	1.5	33
538	Enhancement of pentylenetetrazole-induced seizures by Shigella dysenteriae in LPS-resistant C3H/HeJ mice: role of the host response. Medical Microbiology and Immunology, 2002, 190, 173-178.	4.8	9
539	Title is missing!. Journal of Child and Family Studies, 2002, 11, 441-453.	1.3	24
540	Attitudes Toward Sexuality Among Nursing Home Residents. Sexuality and Disability, 2002, 20, 185-189.	1.0	38

#	Article	IF	CITATIONS
541	SOCIODEMOGRAPHIC FACTORS ASSOCIATED WITH ATTEMPTED SUICIDE IN TWO ISRAELI CITIES BETWEEN 1990 AND 1998. Journal of Nervous and Mental Disease, 2002, 190, 115-118.	1.0	3
542	Abnormal thermoregulation in drug-free male schizophrenia patients. European Neuropsychopharmacology, 2001, 11, 285-288.	0.7	59
543	Stability of diagnosis: a 20-year retrospective cohort study of Israeli psychiatric adolescent inpatients. Journal of Adolescence, 2001, 24, 625-633.	2.4	17
544	Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neuroscience Letters, 2001, 316, 129-132.	2.1	117
545	Obsessive–compulsive disorder in hospitalized patients with chronic schizophrenia. Psychiatry Research, 2001, 102, 49-57.	3.3	150
546	Familial Approach To The Treatment Of Childhood Obesity: Conceptual Model. Journal of Nutrition Education and Behavior, 2001, 33, 102-107.	0.5	227
547	Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. Life Sciences, 2001, 69, 2311-2317.	4.3	30
548	Fatty acid amide hydrolase inhibitors and the marijuana debate. Lancet, The, 2001, 358, 1548.	13.7	2
549	Heart Rate Variability in Elderly Patients Before and After Electroconvulsive Therapy. American Journal of Geriatric Psychiatry, 2001, 9, 255-260.	1.2	22
550	Viewpoint: Obsessive Compulsive Behaviour in Autism - Towards an Autistic-Obsessive Compulsive Syndrome?. World Journal of Biological Psychiatry, 2001, 2, 193-197.	2.6	20
551	Hormonal Regulation of Peripheral Benzodiazepine Receptor Binding Properties Is Mediated by Subunit Interactionâ€. Biochemistry, 2001, 40, 10213-10222.	2.5	50
552	Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: A new approach to an old problem. British Journal of Psychiatry, 2001, 179, 4-8.	2.8	74
553	Cyproheptadine Versus Propranolol for the Treatment of Acute Neuroleptic-Induced Akathisia: A Comparative Double-Blind Study. Journal of Clinical Psychopharmacology, 2001, 21, 612-615.	1.4	65
554	Analysis of neurosteroid levels in attention deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 2001, 4, 259-64.	2.1	69
555	Response of Catatonia to Risperidone: Two Case Reports. Clinical Neuropharmacology, 2001, 24, 228-231.	0.7	28
556	Risperidone-Induced Retrograde Ejaculation. American Journal of Psychiatry, 2001, 158, 650-650.	7.2	23
557	Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. International Journal of Eating Disorders, 2001, 30, 113-117.	4.0	22
558	Plasma serotonin response to carbohydrate-rich food in chronic schizophrenic patients: clozapine versus classic antipsychotic agents. Human Psychopharmacology, 2001, 16, 403-407.	1.5	3

#	Article	IF	CITATIONS
559	Family-based association study of serotonin transporter promoter in suicidal adolescents: No association with suicidality but possible role in violence traits. American Journal of Medical Genetics Part A, 2001, 105, 239-245.	2.4	81
560	Case control and family-based studies of tryptophan hydroxylase gene A218C polymorphism and suicidality in adolescents. American Journal of Medical Genetics Part A, 2001, 105, 451-457.	2.4	45
561	Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cellular and Molecular Neurobiology, 2001, 21, 705-716.	3.3	46
562	Brief report: Children with autism as they grow up-description of adult inpatients with severe autism. Journal of Autism and Developmental Disorders, 2001, 31, 355-360.	2.7	10
563	Attachment Styles and Aggression in Physically Abused and Neglected Children. Journal of Youth and Adolescence, 2001, 30, 769-786.	3.5	107
564	Depressive symptoms and suicidality in physically abused children American Journal of Orthopsychiatry, 2001, 71, 98-107.	1.5	48
565	Acute and Repeated Swim Stress Effects on Peripheral Benzodiazepine Receptors in the Rat Hippocampus, Adrenal, and Kidney,. Neuropsychopharmacology, 2001, 25, 669-678.	5.4	54
566	Animal models and human genome diversity: the pitfalls of inbred mice. Drug Discovery Today, 2001, 6, 766-768.	6.4	10
567	Changes in Vesicular Monoamine Transporter (VMAT2) and Synaptophysin in Rat Substantia nigra and Prefrontal Cortex Induced by Psychotropic Drugs. Neuropsychobiology, 2001, 44, 187-191.	1.9	22
568	Zuclopenthixol Treatment of Behavioral Disturbances in Mentally Retarded Children and Adolescents: An Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 2001, 11, 279-284.	1.3	14
569	Geriatric Depression Scale (GDS-15): A Sensitive and Convenient Instrument for Measuring Depression in Young Anorexic Patients. Journal of Nervous and Mental Disease, 2001, 189, 338-339.	1.0	14
570	Mirtazapine for Neuroleptic-Induced Akathisia. American Journal of Psychiatry, 2001, 158, 819-819.	7.2	23
571	Obsessive-Compulsive Schizophrenia: A New Diagnostic Entity?. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 115-116.	1.8	13
572	Comparison of Sexual Dysfunction in Male Schizophrenic Patients Maintained on Treatment With Classical Antipsychotics Versus Clozapine. Journal of Clinical Psychiatry, 2001, 62, 541-544.	2.2	70
573	Combined Electroconvulsive-Clozapine Therapy. Clinical Neuropharmacology, 2000, 23, 14-16.	0.7	88
574	Myotoxicity and Neurotoxicity during Clozapine Treatment. Clinical Neuropharmacology, 2000, 23, 276-280.	0.7	38
575	Treating Depression in Alzheimer's Disease: Integration of Differing Guidelines. International Psychogeriatrics, 2000, 12, 353-358.	1.0	7
576	Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica, 2000, 102, 226-230.	4.5	20

#	Article	IF	CITATIONS
577	Lifetime psychiatric comorbidity rate in Israeli non-help-seeking patients with combat-related post-traumatic stress disorder. Journal of Affective Disorders, 2000, 57, 185-188.	4.1	5
578	QT dispersion in the surface electrocardiogram in elderly patients with major depression. Journal of Affective Disorders, 2000, 60, 197-200.	4.1	34
579	Attachment styles in maltreated children: a comparative study. Child Psychiatry and Human Development, 2000, 31, 113-128.	1.9	62
580	Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics, 2000, 1, 335-341.	1.3	34
581	Heat Intolerance in Patients With Chronic Schizophrenia Maintained With Antipsychotic Drugs. American Journal of Psychiatry, 2000, 157, 1327-1329.	7.2	71
582	Human Figure Drawings in the Evaluation of Severe Adolescent Suicidal Behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 2000, 39, 1024-1031.	0.5	19
583	Suppression of serum gonadal steroids in rats by chronic treatment with dopamine and serotonin reuptake inhibitors. European Neuropsychopharmacology, 2000, 10, 145-150.	0.7	20
584	Unaltered $\hat{l}\pm 2$ -noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysis. European Neuropsychopharmacology, 2000, 10, 265-271.	0.7	16
585	Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia. European Neuropsychopharmacology, 2000, 10, 389-395.	0.7	66
586	Acute antipsychotic drug administration lowers body temperature in drug-free male schizophrenic patients. European Neuropsychopharmacology, 2000, 10, 443-445.	0.7	24
587	Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biological Psychiatry, 2000, 48, 693-701.	1.3	60
588	Increased Risk for Dementia in Elderly Psychiatric Inpatients with Late-Onset Major Depression. Journal of Nervous and Mental Disease, 2000, 188, 242-243.	1.0	16
589	Is Melatonin Treatment Effective for Tardive Dyskinesia?. Journal of Clinical Psychiatry, 2000, 61, 556-558.	2.2	41
590	Effects of psychotropic drugs on cell proliferation and differentiation. Biochemical Pharmacology, 1999, 58, 1229-1236.	4.4	92
591	Platelet Peripheral-Type Benzodiazepine in Pregnancy and Lactation. Neuropsychopharmacology, 1999, 21, 513-518.	5.4	2
592	The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: An open label study. European Neuropsychopharmacology, 1999, 9, 475-477.	0.7	20
593	Orbitofrontal cortex dysfunction in obsessive-compulsive disorder?. European Neuropsychopharmacology, 1999, 9, 415-420.	0.7	22
594	Orbitofrontal cortex dysfunction in obsessive–compulsive disorder?. European Neuropsychopharmacology, 1999, 9, 407-413.	0.7	37

#	Article	IF	CITATIONS
595	Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. Biological Psychiatry, 1999, 45, 840-845.	1.3	67
596	Decreased platelet peripheral-type benzodiazepine receptors in adolescent inpatients with repeated suicide attempts. Biological Psychiatry, 1999, 46, 484-488.	1.3	44
597	Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients. Biological Psychiatry, 1999, 46, 532-541.	1.3	58
598	Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthmaâ <sup>*</sup> †â <sup>*</sup> †â <sup>*</sup> †â <sup>*</sup> Journal of Allergy and Clinical Immunology, 1999, 104, 1162-1167.	2.9	61
599	Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophrenia Research, 1999, 35, 105-112.	2.0	89
600	Impact of Treatment for Childhood Obesity on Parental Risk Factors for Cardiovascular Disease. Preventive Medicine, 1999, 29, 519-526.	3.4	35
601	<b>Treatment of neuroleptic-induced akathisia with the 5-HT<sub>2</sub> antagonist mianserin</b> . British Journal of Psychiatry, 1999, 174, 238-242.	2.8	71
602	Intramuscular Flunitrazepam Versus Intramuscular Haloperidol in the Emergency Treatment of Aggressive Psychotic Behavior. American Journal of Psychiatry, 1999, 156, 142-144.	7.2	82
603	3H-Spiperone Binding to Lymphocytes in Neuroleptic-Naive-Schizophrenia and the Effect of Neuroleptic Treatment. Clinical Neuropharmacology, 1999, 22, 110-114.	0.7	1
604	The Impact of Clozapine Treatment on Serum Lipids in Chronic Schizophrenic Patients. Clinical Neuropharmacology, 1999, 22, 98-101.	0.7	49
605	Role of Nitric Oxide in the Enhancement of Pentylenetetrazole-Induced Seizures Caused by (i) Shigella dysenteriae (i). Infection and Immunity, 1999, 67, 6364-6368.	2.2	18
606	Involvement of Tumor Necrosis Factor Alpha and Interleukin- $\hat{\mathbb{1}}^2$ in Enhancement of Pentylenetetrazole-Induced Seizures Caused by Shigella dysenteriae. Infection and Immunity, 1999, 67, 1455-1460.	2.2	48
607	Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 melanoma cells. Biochemical Pharmacology, 1998, 56, 1029-1034.	4.4	58
608	Psychiatric and polysomnographic evaluation of sleep disturbances. Journal of Affective Disorders, 1998, 49, 27-30.	4.1	15
609	Elevated adhesiveness/aggregation of peripheral blood leukocytes in patients with major depression. Journal of Affective Disorders, 1998, 50, 3-9.	4.1	14
610	Interventional catheterization decreases plasma levels of atrial natriuretic peptide (ANP) in children with congenital heart defects. Catheterization and Cardiovascular Diagnosis, 1998, 45, 27-32.	0.3	5
611	Linkage disequilibrium of common Gaucher disease mutations with a polymorphic site in thepyruvate kinase (PKLR) gene., 1998, 78, 233-236.		8
612	Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Molecular Brain Research, 1998, 57, 31-37.	2.3	59

#	Article	lF	Citations
613	The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neuroscience Letters, 1998, 253, 183-186.	2.1	29
614	Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis. Biological Psychiatry, 1998, 43, 288-292.	1.3	30
615	Bone age in adolescents with schizophrenia and obsessive-compulsive disorder. Schizophrenia Research, 1998, 33, 119-122.	2.0	3
616	Sleep Disturbances in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Learning Disabilities, 1998, 31, 572-578.	2.2	78
617	Elevated surum creatine kinase activity in adolescent psychiatric inpatients on admission. International Clinical Psychopharmacology, 1998, 13, 269-272.	1.7	6
618	Belief in Transmigration of the Soul and Psychopathology in Israeli Druze. Psychopathology, 1998, 31, 52-58.	1.5	4
619	Intravenous Clomipramine for a Schizophrenic Patient With Obsessive-Compulsive Symptoms. American Journal of Psychiatry, 1998, 155, 993-993.	7.2	11
620	Use of Atypical Neuroleptics in Child and Adolescent Psychiatry. Journal of Clinical Psychiatry, 1998, 59, 644-656.	2.2	69
621	Iron Treatment in Children with Attention Deficit Hyperactivity Disorder. Neuropsychobiology, 1997, 35, 178-180.	1.9	112
622	THE ROLE OF INTELLIGENCE AND HYPERACTIVITY IN DIAGNOSIS OF ATTENTION DEFICIT DISORDER IN CHILDREN AND ADOLESCENTS. International Journal of Adolescent Medicine and Health, 1997, 9, 165-172.	1.3	0
623	Reduction of Aggressiveness and Impulsiveness during Clozapine Treatment in Chronic Neuroleptic-Resistant Schizophrenic Patients. Clinical Neuropharmacology, 1997, 20, 442-446.	0.7	54
624	Significant Inhibition of Spontaneous IgA Secretion by Selective Peripheral-Type Benzodiazepine Receptor Ligands. Clinical Neuropharmacology, 1997, 20, 215-223.	0.7	5
625	Mianserin, a 5-HT2a/2c and $\hat{l}\pm 2$ Antagonist, in the Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors. Clinical Neuropharmacology, 1997, 20, 210-214.	0.7	43
626	Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. British Journal of Psychiatry, 1997, 171, 569-573.	2.8	256
627	Evidence for an infectious etiology in autism. Pathophysiology, 1997, 4, 91-96.	2.2	9
628	Elevated levels of serum interleukin- $\hat{l}^2$ in combat-related posttraumatic stress disorder. Biological Psychiatry, 1997, 42, 345-348.	1.3	193
629	Neuroleptic malignant syndrome with gangliosidosis type II. Biological Psychiatry, 1997, 41, 1222-1224.	1.3	10
630	Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Research, 1997, 756, 153-159.	2.2	84

#	Article	IF	CITATIONS
631	Successful treatment of fluoxetine-indueed dystonia with low-dose mianserin. Movement Disorders, 1997, 12, 1102-1105.	3.9	17
632	Desmopressin (DDAVP) treatment in adult sleep-related enuresis. Human Psychopharmacology, 1997, 12, 505-507.	1.5	0
633	Velocardiofacial manifestations and microdeletions in schizophrenic inpatients., 1997, 72, 455-461.		68
634	Selective Serotonin Reuptake Inhibitor and Akathisia. Journal of Clinical Psychopharmacology, 1997, 17, 489.	1.4	2
635	Clozapine Treatment for Neuroleptic-Induced Tardive Dyskinesia, Parkinsonism, and Chronic Akathisia in Schizophrenic Patients. Journal of Clinical Psychiatry, 1997, 58, 318-322.	2.2	99
636	Hypothalamic-pituitary-ovarian axis and mood. Biological Psychiatry, 1996, 40, 1051-1055.	1.3	14
637	Depression in women treated with a gonadotropinreleasing hormone agonist. Biological Psychiatry, 1996, 39, 378-382.	1.3	17
638	Fluvoxamine Treatment in Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenic Patients. Clinical Neuropharmacology, 1996, 19, 305-313.	0.7	57
639	Lithium and Male Sexual Function in Affective Patients. Clinical Neuropharmacology, 1996, 19, 515-519.	0.7	46
640	Low-Dose imipramine for thioridazineinduced male orgasmic disorder. Journal of Sex and Marital Therapy, 1996, 22, 225-229.	1.5	19
641	Auditory Pseudohallucinations Induced by a Combination of Hearing Impairment and Environmental Stress. Psychopathology, 1996, 29, 198-200.	1.5	4
642	Serotonergic Drugs in Trichotillomania: Treatment Results in 12 Patients. Journal of Nervous and Mental Disease, 1996, 184, 641-644.	1.0	28
643	Cyproheptadine Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors. Clinical Neuropharmacology, 1995, 18, 320-324.	0.7	71
644	Catatonia as an Unusual Presentation of Posttraumatic Stress Disorder. Psychopathology, 1995, 28, 285-290.	1.5	31
645	Cyproheptadine Treatment in Neuroleptic-Induced Akathisia. British Journal of Psychiatry, 1995, 167, 483-486.	2.8	53
646	The Belief in the Transmigration of Souls as a Presenting Symptom of Generalized Anxiety Disorder in a Military Setting. Psychopathology, 1995, 28, 158-160.	1.5	6
647	Suicide as a Work Accident. Journal of Forensic Psychiatry Psychology, 1995, 6, 516-526.	0.3	1
648	Caffeine withdrawal increases lithium blood levels. Biological Psychiatry, 1995, 37, 348-350.	1.3	61

#	Article	IF	Citations
649	Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biological Psychiatry, 1995, 38, 297-302.	1.3	90
650	Effect of melatonin on active transport of serotonin into blood platelets. Psychiatry Research, 1995, 57, 193-196.	3.3	12
651	Platelet peripheral-type benzodiazepine receptor in major depression. Journal of Affective Disorders, 1995, 33, 257-261.	4.1	33
652	Anticipatory consent for psychiatric treatment: A potential solution for an ethical problem. Journal of Forensic Psychiatry Psychology, 1994, 5, 160-167.	0.3	7
653	Platelet serotonin transporter in drug-naive migrainous children and adolescents. Biological Psychiatry, 1994, 35, 452-456.	1.3	4
654	Tourette's disorder: Is there an association with the antiphospholipid syndrome?. Biological Psychiatry, 1994, 35, 495-498.	1.3	21
655	Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity. Brain Research, 1994, 646, 235-241.	2.2	31
656	Fluvoxamine Open-Label Treatment of Adolescent Inpatients with Obsessive-Compulsive Disorder or Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 1994, 33, 342-348.	0.5	104
657	Clozapine Treatment in Very Early Onset Schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 1994, 33, 65-70.	0.5	68
658	The Sociocultural Theory in the Development of Anorexia nervosa. Psychopathology, 1994, 27, 29-36.	1.5	23
659	Verapamil Is Not an Antidepressant in Patients Resistant to Tricyclic Antidepressants. Clinical Neuropharmacology, 1994, 17, 298-302.	0.7	7
660	Adrenal mitochondrial benzodiazepine receptors are sensitive to agents active at the dopamine receptor. Biochemical Pharmacology, 1993, 45, 999-1002.	4.4	6
661	Hippocampal $\hat{I}^3$ -aminobutyric acid and benzodiazepine receptors after early phenobarbital exposure. Developmental Brain Research, 1993, 74, 111-116.	1.7	6
662	Reduced total complement haemolytic activity in schizophrenic patients. Psychological Medicine, 1993, 23, 315-318.	4.5	29
663	CLINICAL COMMENTS. Clinical Gerontologist, 1993, 12, 97-106.	2.2	2
664	Long-Term Testosterone or Diethylstilbestrol Treatment Affects Gamma-Aminobutyric Acid and Central-Type Benzodiazepine Receptors but Not Peripheral-Type Benzodiazepine Receptors in the Female Rat Brain. Neuroendocrinology, 1993, 57, 1114-1118.	2.5	9
665	Survey of Smoking Habits and Attitudes of Patients and Staff in Psychiatric Hospitals. Psychopathology, 1993, 26, 69-75.	1.5	29
666	Ro 5-4864 and PK 11195, but Not Diazepam, Depress Cardiac Function in an Isolated Working Rat Heart Model. Pharmacology, 1993, 46, 224-230.	2.2	16

#	Article	lF	CITATIONS
667	Risk for Definite Neuroleptic Malignant Syndrome. British Journal of Psychiatry, 1992, 161, 254-257.	2.8	69
668	??-Tocopherol Treatment for Tardive Dyskinesia. Journal of Nervous and Mental Disease, 1992, 180, 400-401.	1.0	21
669	Decreased platelet imipramine binding in tourette syndrome children with obsessive-compulsive disorder. Biological Psychiatry, 1992, 31, 705-711.	1.3	27
670	Acute Transient Stress-Induced Hallucinations in Soldiers. British Journal of Psychiatry, 1992, 160, 412-414.	2.8	10
671	Testosterone prevents castration-induced reduction in peripheral benzodiazepine receptors in Cowper's gland and adrenal. Brain Research, 1992, 572, 72-75.	2.2	17
672	Platelet peripheral benzodiazepine receptors in repeated stress. Life Sciences, 1991, 48, 341-346.	4.3	31
673	Behavioral Profile and Social Competence in Temporal Lobe Epilepsy of Adolescence. Journal of the American Academy of Child and Adolescent Psychiatry, 1991, 30, 887-892.	0.5	32
674	TRH stimulation test in obsessive-compulsive patients. Psychiatry Research, 1991, 38, 21-26.	3.3	11
675	True Conversive Hallucinations. Psychopathology, 1991, 24, 19-24.	1.5	3
676	Platelet benzodiazepine binding in Alzheimer's disease. Biological Psychiatry, 1990, 28, 641-643.	1.3	18
677	Long-term verapamil treatment increases [3H]imipramine binding in human platelets. European Journal of Pharmacology, 1990, 181, 311-314.	3.5	2
678	Identification and distribution of peripheral benzodiazepine binding sites in male rat genital tract. Biochemical Pharmacology, 1990, 40, 817-820.	4.4	23
679	Effect of prenatal and neonatal chronic exposure to phenobarbital on central and peripheral benzodiazepine receptors. Brain Research, 1990, 506, 115-119.	2.2	10
680	Food deprivation modulates $\hat{i}^3$ -aminobutyric acid receptors and peripheral benzodiazepine binding sites in rats. Brain Research, 1990, 535, 96-100.	2.2	27
681	LIGANDS SPECIFIC TO PERIPHERAL BENZODIAZEPINE RECEPTORS FOR TREATMENT OF PORPHYRIAS. Lancet, The, 1989, 333, 932-933.	13.7	5
682	Chronic phenobarbital administration affects GABA and benzodiazepine receptors in the brain and periphery. European Journal of Pharmacology, 1989, 169, 235-240.	3.5	10
683	Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Research, 1989, 487, 45-51.	2.2	153
684	Examination stress, platelet peripheral benzodiazepine binding sites, and plasma hormone levels. Life Sciences, 1989, 44, 1077-1082.	4.3	44

#	Article	IF	CITATIONS
685	Primary Hyperparathyroidism, Psychiatric Manifestations, Diagnosis and Management. Psychotherapy and Psychosomatics, 1989, 51, 38-44.	8.8	15
686	Suicide by Related Kidney Donors following the Recipients' Death. Psychotherapy and Psychosomatics, 1989, 51, 216-219.	8.8	45
687	Tricyclic antidepressants and calcium channel blockers: interactions at the (â^')-desmethoxyverapamil binding site and the serotonin transporter. European Journal of Pharmacology, 1988, 155, 1-9.	3.5	27
688	Up-regulatory effect of triphasic oral contraceptive on platelet 3H-imipramine binding sites. Psychiatry Research, 1988, 23, 23-29.	3.3	19
689	Imipramine binding to platelets of children with attention deficit disorder with hyperactivity. Biological Psychiatry, 1988, 23, 491-496.	1.3	18
690	The Sigma Receptor. Clinical Neuropharmacology, 1988, 11, 105-119.	0.7	77
691	Plasma Cortisol, Prolactin, Growth Hormone, and Immunoreactive $\hat{l}^2$ -Endorphin Response to Fenfluramine Challenge in Depressed Patients. Clinical Neuropharmacology, 1988, 11, 250-256.	0.7	48
692	Clomipramine-Induced Urinary Dysfunction in an Obsessive-Compulsive Adolescent. Drug Intelligence & Clinical Pharmacy, 1987, 21, 877-879.	0.4	11
693	Carbamazepine up-regulates the binding of [3H]PK 11195 to platelets of epileptic patients. European Journal of Pharmacology, 1987, 141, 471-474.	3.5	18
694	Regulation of central and peripheral benzodiazepine receptors in progesterone-treated rats. Brain Research, 1987, 409, 386-390.	2.2	48
695	Ontogenetic development of peripheral benzodiazepine binding sites in rat brain, heart and lung. Brain Research, 1987, 408, 381-384.	2.2	21
696	Upregulation of imipramine binding and serotonin uptake by estradiol in female rat brain. Brain Research, 1987, 410, 135-139.	2.2	65
697	Modulation of peripheral benzodiazepine binding sites following chronic estradiol treatment. European Journal of Pharmacology, 1986, 127, 147-151.	3.5	43
698	Decreased peripheral benzodiazepine binding sites in platelets of neuroleptic-treated schizophrenics. European Journal of Pharmacology, 1986, 121, 275-279.	3.5	54
699	Behavior Therapy, Pimozide Treatment and Prolactin Secretion in Anorexia Nervosa. Psychotherapy and Psychosomatics, 1985, 43, 136-140.	8.8	24
700	Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985, 9, 193-198.	4.8	12
701	Decreased high affinity 3H-imipramine binding in platelets of enuretic children and adolescents. Psychiatry Research, 1985, 14, 39-46.	3.3	21
702	High dose diazepam treatment and its effect on prolactin secretion in adolescent schizophrenic patients. Psychopharmacology, 1984, 82, 382-385.	3.1	15

#	Article	IF	CITATION
703	Combination of Neuroleptic and Stimulant Treatment in Attention Deficit Disorder with Hyperactivity. Journal of the American Academy of Child Psychiatry, 1984, 23, 295-298.	0.7	32
704	Sexual Dysfunction Associated with Hyperprolactinemia in Males and Females Undergoing Hemodialysis. Psychosomatic Medicine, 1983, 45, 259-269.	2.0	37
705	The Correlation of Increased Serum Prolactin Levels with Decreased Sexual Desire and Activity in Elderly Men. Journal of the American Geriatrics Society, 1983, 31, 485-488.	2.6	31
706	Dr. Weizman and Associates Reply. American Journal of Psychiatry, 1983, 140, 1261-1261.	7.2	0
707	Abnormal Growth Hormone Response to TRH in Chronic Adolescent Schizophrenic Patients. British Journal of Psychiatry, 1982, 141, 582-585.	2.8	11
708	Hyperprolactinemia: A Possible Cause of Sexual Impotence in Male Patients Undergoing Chronic Hemodialysis. Nephron, 1980, 26, 53-54.	0.6	14
709	The Potential Usefulness Of The Social Attribution Task (SAT) in Diagnosing Girls with ASD. International Journal of Disability Development and Education, 0, , 1-6.	1.1	0